Northwest Biotherapeutics (NWBO) 10-K 17 Apr 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 14, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	NORTHWEST BIOTHERAPEUTICS INC
Entity Central Index Key	1,072,379
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 32,379,666
Trading Symbol	NWBO
Entity Common Stock, Shares Outstanding		186,061,822

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 6,186	$ 21,813
Restricted cash - interest payments held in escrow	685	886
Prepaid expenses and other current assets	1,013	1,402
Total current assets	7,884	24,101
Non-current assets:
Property, plant and equipment, net	315	476
Restricted cash - interest payments held in escrow, net of current portion	0	349
Construction in progress (property in the United Kingdom)	44,559	45,681
Other assets	148	190
Total non-current assets	45,022	46,696
Total assets	52,906	70,797
Current liabilities:
Accounts payable	12,378	11,721
Accounts payable to related party	23,353	5,455
Accrued expenses (includes related party of $40 and $11 as of December 31, 2016 and 2015, respectively)	901	1,309
Convertible notes (net of deferred financing cost of $175 and $0 as of December 31, 2016 and 2015, respectively)	10,960	135
Share settled debt, at fair value (in default)	5,200	0
Notes payable (includes related party note of $310 and $50 as of December 31, 2016 and 2015, respectively	2,760	50
Note payable - in dispute	0	934
Mortgage loan (net of deferred financing cost of $365 and $468 as of December 31, 2016 and 2015, respectively)	9,791	11,144
Environmental remediation liability	6,200	6,200
Derivative liability	4,862	27,982
Total current liabilities	76,405	64,930
Non-current liabilities:
Convertible note (net of deferred financing cost of $457 as of December 31, 2015)	0	10,543
Note payable, net of current portion (net of debt discount of $310 as of December 31, 2016)	3,000	0
Total non-current liabilities	3,000	10,543
Total liabilities	79,405	75,473
Commitments and Contingencies
Stockholders' equity (deficit):
Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2016 and 2015, respectively	0	0
Common stock ($0.001 par value); 450,000,000 shares authorized; 157,028,270 and 95,858,087 shares issued and outstanding as of December 31, 2016 and 2015, respectively	157	96
Additional paid-in capital	686,972	630,613
Accumulated deficit	(715,476)	(635,262)
Accumulated other comprehensive gain (loss)	1,848	(123)
Total stockholders' equity (deficit)	(26,499)	(4,676)
Total liabilities and stockholders' equity (deficit)	$ 52,906	$ 70,797

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued expenses, related party net (in dollars)	$ 40	$ 11
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	157,028,270	95,858,087
Common stock, shares outstanding	157,028,270	95,858,087
Due to Related Parties, Current	$ 310	$ 50
Debt Instrument, Unamortized Discount, Noncurrent	310
Convertible Debt [Member]
Debt Issuance Costs, Current, Net (in dollars)	175	0
Debt Issuance Costs, Noncurrent, Net (in dollars)		457
Mortgage Loan [Member]
Debt Issuance Costs, Current, Net (in dollars)	$ 365	$ 468

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Research and other	$ 623	$ 1,739
Total revenues	623	1,739
Operating costs and expenses:
Research and development	60,081	103,120
General and administrative	10,867	18,326
Legal expenses	8,941	6,577
Total operating costs and expenses	79,889	128,023
Loss from operations	(79,266)	(126,284)
Other income (expense):
Loss from assumption of Cognate BioServices debt	(5,680)	0
Inducement loss from exercise of derivative warrants	(1,457)	0
Change in fair value of derivative liability	17,891	15,676
Loss from extinguishment of debt	(1,152)	0
Interest expense	(3,818)	(4,153)
Foreign currency transaction gain (loss)	(6,732)	20
Net loss	(80,214)	(114,741)
Deemed dividend related to warrant modification	(5,647)	0
Net loss applicable to common stockholders	$ (85,861)	$ (114,741)
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)	$ (0.77)	$ (1.48)
Net earnings (loss) per share applicable to common stockholders
Weighted average shares used in computing basic and diluted loss per share (in shares)	111,078	77,713

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (80,214)	$ (114,741)
Other comprehensive loss
Foreign currency translation adjustment	1,971	67
Total comprehensive loss	$ (78,243)	$ (114,674)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Cumulative Translation Adjustment [Member]
Balance at Dec. 31, 2014	$ (35,027)	$ 69	$ 485,615	$ (520,521)	$ (190)
Balance (in shares) at Dec. 31, 2014		68,957
Proceeds from issuance of common stock, net of offering cost	81,662	$ 14	81,648	0	0
Proceeds from issuance of common stock, net of offering cost (in shares)		14,360
Redeemable securities settlement	299	$ 0	299	0	0
Redeemable securities settlement (in shares)		80
Issuance of common stock for debt conversion	6,500	$ 1	6,499	0	0
Issuance of common stock for debt conversion (in shares)		985
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices	3,751	$ 1	3,750	0	0
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices (in shares)		682
Issuance of common stock for conversion of accrued interest	387	$ 0	387	0	0
Issuance of common stock for conversion of accrued interest (in Shares)		39
Proceeds from exercise of warrants	7,430	$ 2	7,428	0	0
Proceeds from exercise of warrants (In shares)		1,728
Cashless warrants exercise	521	$ 1	520	0	0
Cashless warrants exercise (in shares)		572
Shares payment due to Cognate BioServices	3,389	$ 0	3,389	0	0
Shares payment due to Cognate BioServices (in Shares)		403
Stock issued to Cognate BioServices as compensation under Cognate Agreements (in Shares)		8,052
Stock issued to Cognate BioServices as compensation under Cognate Agreements	40,765	$ 8	40,757	0	0
Issuance of warrants in conjunction with demand notes	57	0	57	0	0
Reclassification of warrant liabilities related to warrants exercised for cash	264	0	264	0	0
Net loss	(114,741)	0	0	(114,741)	0
Cumulative translation adjustment	67	0	0	0	67
Balance at Dec. 31, 2015	(4,676)	$ 96	630,613	(635,262)	(123)
Balance (in shares) at Dec. 31, 2015		95,858
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices	28	$ 0	28	0	0
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices (in shares)		78
Issuance of common stock and warrants for cash in a registered direct offering	19,987	$ 42	19,945	0	0
Issuance of common stock and warrants for cash in a registered direct offering (in shares)		41,857
Offering cost related to registered direct offering	(1,877)	$ 0	(1,877)	0	0
Issuance of common stock and warrants for cash in private offering	2,206	$ 7	2,199	0	0
Issuance of common stock and warrants for cash in private offering (in Shares)		6,377
Warrants exercised for cash	8,066	$ 15	8,051	0	0
Warrants exercised for cash (in shares)		15,357
Offering costs related to warrants exercise	(795)	$ 0	(795)	0	0
Modification on warrant exercise price	5,647	0	5,647	0	0
Deemed dividend related to warrant exercise price modification	(5,647)	0	(5,647)	0	0
Issuance of common stock and warrants for debt and accrued interest conversion	3,021	$ 6	3,015	0	0
Issuance of common stock and warrants for debt and accrued interest conversion (in Shares)		6,035
Common stock issued as compensation	127	$ 0	127	0	0
Common stock issued as compensation (in shares)		250
Return of common stock and warrants from Cognate	0	$ (8)	8	0	0
Return of common stock and warrants from Cognate (in Shares)		(8,052)
Extinguishment of shares payable related to Cognate	22,539	$ 0	22,539	0	0
Extinguishment of derivative liabilities related to Cognate	10,131	0	10,131	0	0
Shares payment due to Cognate BioServices	(8,885)	$ (1)	(8,884)	0	0
Shares payment due to Cognate BioServices (in Shares)		(732)
Reclassification of warrant liabilities related to warrants exercised for cash	1,872	$ 0	1,872	0	0
Net loss	(80,214)	0	0	(80,214)	0
Cumulative translation adjustment	1,971	0	0	0	1,971
Balance at Dec. 31, 2016	$ (26,499)	$ 157	$ 686,972	$ (715,476)	$ 1,848
Balance (in shares) at Dec. 31, 2016		157,028

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows from Operating Activities:
Net Loss	$ (80,214)	$ (114,741)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	189	56
Amortization of debt discount and accretion on redeemable securities	0	57
Amortization of deferred financing cost	850	1,248
Change in fair value of derivatives	(17,891)	(15,676)
Inducement loss	1,457	0
Loss from extinguishment of debt	1,152	0
Loss from assumption of Cognate BioServices share settled debt (in default)	5,680	0
Stock and warrants issued to Cognate BioServices	13,654	40,765
Common stock issued as compensation	127	3,389
Correction on debt from prior period	0	(53)
Subtotal of non-cash charges	5,218	29,786
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	366	(478)
Accounts payable and accrued expenses	1,037	2,809
Related party accounts payable and accrued expenses	17,899	3,048
Other non-current assets	42	(135)
Net cash used in operating activities	(55,652)	(79,711)
Cash Flows from Investing Activities:
Purchase of property, plant and equipment	(4,939)	(6,751)
Net cash used in investing activities	(4,939)	(6,751)
Cash Flows from Financing Activities:
Proceeds from mortgage loan	0	4,997
Deferred offering cost related to mortgage loan	0	(138)
Proceeds from issuance of notes payable	5,450	0
Proceeds from issuance of notes payable to related party	260	1,400
Repayment of notes payable to related parties	0	(1,400)
Proceeds from issuance of common stock and warrants in a registered direct offering	19,987	81,662
Offering cost related to registered direct offering	(1,077)	0
Proceeds from issuance of common stock and warrants in private offering	6,417	0
Warrants exercised for cash	8,066	7,430
Offering costs related to warrants exercise	(795)	0
Net cash provided by financing activities	38,308	93,951
Effect of exchange rate changes on cash and cash equivalents	6,106	(456)
Net (decrease) increase in cash, cash equivalents and restricted cash	(16,177)	7,033
Cash, cash equivalents and restricted cash, beginning of the year	23,048	16,015
Cash, cash equivalents and restricted cash, end of the year	6,871	23,048
Supplemental schedule of non-cash investing and financing activities:
Deemed dividend related to modification of warrant	5,647	0
Issuance of debt with debt discount	310	0
Return of common stock and warrants from Cognate	8	0
Extinguishment of shares payable related to Cognate	22,539	0
Extinguishment of derivative liabilities related to Cognate	10,131	0
Issuance of warrants in conjunction with demand notes	0	57
Issuance of common stock for accounts payable conversion	28	0
Issuance of common stock and warrants in connection with conversion of accounts payable - Cognate BioServices	0	3,751
Issuance of common stock and warrants for conversion of debt and accrued interest	1,869	6,887
Accrued renewal fee incurred from mortgage loan	488	0
Accrued exit fee incurred from mortgage loan	0	51
Offering costs payable	800	0
Reclassification of warrant liabilities related to warrants exercised for cash	825	264
Reclassification of warrant liabilities related to cashless warrants exercise	0	521
VAT receivable related to UK facility	0	537
Redeemable security settlement	0	299
Mortgage Loan [Member]
Supplemental disclosure of cash flow information
Interest payments	(1,784)	(1,369)
Convertible Notes Payable [Member]
Supplemental disclosure of cash flow information
Interest payments	$ (550)	$ (1,103)

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Description of Business Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio Gmbh, and Aracaris Capital, Ltd (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company is developing an experimental dendritic cell vaccine using its platform technology known as DCVax. DCVax is currently being tested for use in the treatment of certain types of cancers. Cognate BioServices, Inc. (“Cognate BioServices”), which is a company related by common ownership (Note 9), provides the Company with mission critical contract manufacturing services, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements for clinical grade cellular products. The Company and Cognate BioServices are currently parties to a series of contracts providing for these services as more fully described below. The Company is dependent on Cognate BioServices to provide the manufacturing services, and any interruption of such services could potentially have a material adverse effect on the Company’s ability to proceed with its clinical trials. Cognate BioServices’ manufacturing facility for clinical-grade cellular products is located in Memphis, Tennessee. In addition, a Cognate affiliate in Germany works with the Fraunhofer Institute to produce DCVax-L products there, and Cognate affiliates Although there are many contract manufacturers for small molecule drugs and for biologics, there are only a few contract manufacturers in the U.S., and even fewer in Europe, that specialize in producing living cell products and that have a track record of success with regulatory authorities. The manufacturing of living cell products is highly specialized and entirely different than production of biologics: the physical facilities and equipment are different, the types of personnel and skill sets are different, and the processes are different. The regulatory requirements relating to manufacturing and cellular products are especially challenging and are one of the most frequent reasons for the development of a company’s cellular products to be put on clinical hold (i.e., stopped by regulatory authorities). In addition, the Company’s programs require a large amount of capacity in these specialized manufacturing facilities, and require that the large capacity be dedicated exclusively to the Company’s programs. Most medical products, including cellular products, are made in standardized batches: the same manufacturing suites are used for a number of companies’ products, at designated times scheduled in advance. In contrast, the Company’s products are fully personalized and not made in standardized batches: the Company’s products are made on demand, patient by patient, on an as needed basis.

Liquidity, Financial Condition

Liquidity, Financial Condition and Management Plans	12 Months Ended
	Dec. 31, 2016
Liquidity [Abstract]
Liquidity and Financial Condition [Text Block]	2. Liquidity, Financial Condition and Management Plans The Company used approximately $ 55.7 80.2 5.8 The Company had current assets of $ 7.9 68.5 23.7 Because of recurring operating losses, net operating cash flow deficits, and an accumulated deficit, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany and the United Kingdom. All intercompany transactions and accounts have been eliminated in consolidation. The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities which meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE. Certain prior period amounts that were combined in the December 31, 2015 consolidated financial statements have been reclassified for comparability with the December 31, 2016 presentation. These reclassifications had no effect on previously reported net loss. Cash consists of funds deposited in checking accounts. The Company has them either in a form of bank deposits or highly liquid debt instruments in investment-grade pursuant to the Company's investment policy. Accounts at each institution are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $ 250,000 5.8 The Company records cash held in an escrow account to secure certain debt interest obligations as restricted cash. As of December 31, 2016 and 2015, the Company has $ 0.7 1.2 Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. For more details see Note 6. The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amounts or fair value less cost to sell. Management determines fair value using the discounted cash flow method or other accepted valuation techniques. Accordingly, during the year ended December 31, 2016, an assessment was undertaken to determine whether $ 44.6 The Company’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered, and therefore there was no impairment as of December 31, 2016. Of course, it is possible that the estimate of undiscounted cash flows could change at some time in the future, resulting in a need at that time to write down such assets to fair value. In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply, and the fair value of environmental remediation liabilities. ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The carrying amount of the Company’s financial instruments, including cash and cash equivalents and accounts payable approximate their fair values. As of December 31, 2016, the carrying amount of the notes payable approximate fair value as its interest rate approximates current market rates. The Company capitalizes costs related to the issuance of debt which are included on the accompanying consolidated balance sheets. Deferred financing costs are amortized using a straight-line method that approximates the interest method over the life of the related loan and are included as a component of interest expense on the accompanying consolidated statements of operations. The Company accounts for the common stock warrants outstanding as of December 31, 2016 in accordance with the guidance contained in ASC 815-40-15-7D, "Contracts in Entity's Own Equity" whereby under that provision they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company in connection with the Conversion Transaction has been estimated using a Monte Carlo simulation. In addition, Under ASC 815, registered common stock warrants that require the issuance of registered shares upon exercise and do not expressly preclude an implied right to cash settlement are accounted for as derivative liabilities. The Company classifies these derivative warrant liabilities on the consolidated balance sheet as a current liability. The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The reduction in the liability resulting from the completion of the clean-up is included in other income. As of December 31, 2016, the Company estimate that the total environmental remediation costs associated with the purchase of the UK Facility will amount to approximately $ 6.2 6.2 4.5 32.0 The Company has operations in Germany and the United Kingdom in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity (deficit). During the year ended December 31, 2016, the Company recorded $ 2.0 During the year ended December 31, 2016, the Company also recorded $ 6.7 The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, is excluded from net loss. The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. Due to potential collectability issues with patients, the Company has adopted a policy of recognizing these payments as revenue when received. Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively "CROs"). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites. Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs. Research and development costs were approximately $ 60.1 103.1 The Company recognizes income taxes on an accrual basis based on tax positions taken or expected to be taken in its tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however prior to 1998 the Company was a limited liability company and the Company’s tax losses and credits generally flowed directly to the members. Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. The Company estimates pre-vesting option forfeitures at the time of grant and reflects the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. The Company accounts for stock based compensation awards issued to non-employees for services, at either the fair value of the services or the instruments issued in exchange for such services (based on the same methodology described for employee stock based compensation), whichever is more readily determinable. The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished should be recognized as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under "other income (expense)" as loss from extinguishment of convertible debt. Share-settled debt may settle by providing the holder with a variable number of shares with an aggregate fair value equaling the debt principal outstanding. (In some cases, a discount to the fair value of the share price may be used to determine the number of shares to be delivered, resulting in settlement at a premium.) Share-settled debt was analyzed to determine that the share settled debt does not contain a beneficial conversion feature or contingent beneficial conversion feature. Share-settled debt is recorded at fair value. As of October 13, 2016, the Company adopted a sequencing policy whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares (including redeemable shares) plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share. The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented herein. Going Concern In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-15, “Presentation of Financial Statements - Going Concern”, which provide guidance about management's responsibility in evaluating whether there is substantial doubt relating to an entity’s ability to continue as a going concern and to provide related footnote disclosures as applicable. ASU 2014-15 is effective for the interim and annual periods ending after December 15, 2016 and the Company adopted the provisions of ASU 2014-15 as of December 31, 2016. There was no impact from adoption of this guidance on the Company's consolidated financial statements. Interest - Imputation of Interest In August 2015, the FASB issued ASU No. 2015-15, “Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the treatment of debt issuance costs from line-of-credit arrangements after the adoption of ASU No. 2015-03, “Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. In particular, ASU No. 2015-15 clarifies that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to a line-of-credit arrangement as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of such arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted ASU No. 2015-15 during the first quarter of fiscal 2016, and its adoption did not have a material impact on its consolidated financial statements. Restricted Cash In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 during the three months ended December 31, 2016 on a retrospective basis. As a result, net cash provided by operating activities increased by $ 1.1 1.2 December 31, 2016 December 31, 2015 Cash and cash equivalents $ 6,186 $ 21,813 Restricted cash 685 1,235 Total cash and restricted cash $ 6,871 $ 23,048 Statement of Cash Flows In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which addresses specific cash flow classification issues where there is currently diversity in practice including debt prepayment and proceeds from the settlement of insurance claims. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently assessing the impact that ASU No. 2016-15 will have on its consolidated financial statements. Compensation-Stock Compensation In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting Revenue from Contracts with Customer In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, an updated standard on revenue recognition. ASU No. 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU No. 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. The Company is currently evaluating the pending adoption of ASU 2014-09 and its impact on the Company's consolidated financial statements and has not yet identified which transition method will be applied upon adoption. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customer Recognition and Measurement of Financial Assets and Financial Liabilities In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities Leases In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840)

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Fair Value Measurements Extinguishment of Derivative Liabilities related to Cognate On May 2, 2016, the Company submitted a remediation plan (the “Remediation Plan”) related to certain stock previously issued to Cognate to regain compliance with Nasdaq’s Rule 5635. The Remediation Plan was accepted by Nasdaq on August 30, 2016. Pursuant to the Remediation Plan, the Company canceled the most favored nation provisions related to warrants and common shares issued to Cognate under 2013 Manufacturing Services agreement (“2013 Agreement”) and 2014 Manufacturing Services Agreements (“2014 Agreements”) through a binding agreement with Cognate. In addition, Cognate returned and the Company extinguished 6,880,574 4.00 4,305,772 4.27 4.3 403,000 , and was recorded in the additional paid in capital. 10.1 Date of valuation August 30, 2016 Strike price $ 0.35 Contractual term (years) 2.8 Volatility (annual) 81 % Risk-free rate 1 % Dividend yield (per share) 0 % Derivative Warrants Granted in 2016 Public and Private Offering During the year ended December 31, 2016, the Company issued 15,819,000 643,000 0.35 Since the Company’s adopted sequencing policy (see FN 3), the warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other income on the statement of operation and disclosed in the financial statements as long as the contracts remain classified as 2016 Warrants Granted Strike price $ 0.36 Contractual term (years) 5.0 Volatility (annual) 99 % Risk-free rate 2 % Dividend yield (per share) 0 % Debt Conversion During the year ended December 31, 2016, the Company issued 6,034,000 2,517,000 2.5 2016 Warrants Granted Strike price $ 0.48 Contractual term (years) 5.5 Volatility (annual) 137 % Risk-free rate 1 % Dividend yield (per share) 0 % Share settled Debt The fair value of share settled debt (in default) was valued based upon the closing price of the Company’s common stock as of October 13, 2016 and December 31, 2016. Extinguishment of Warrant Liabilities Related to Cash Exercise 2,555,000 2016 Warrants Exercises Strike price $ 0.35 Contractual term (years) 2.2 Volatility (annual) 84 % Risk-free rate 1 % Dividend yield (per share) 0 % The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December 31, 2016 and 2015 (in thousands): Fair value measured at December 31, 2016 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2016 (Level 1) (Level 2) (Level 3) Derivative liability $ 4,862 $ - $ - $ 4,862 Share-settled debt (in default) 5,200 5,200 Total fair value $ 10,062 $ - $ - $ 10,062 Fair value measured at December 31, 2015 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Derivative liability $ 27,982 $ - $ - $ 27,982 There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2016 and 2015, respectively. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2016 and 2015. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Warrant Share-settled Liability Debt (in Default) Total Balance – January 1, 2015 $ 44,742 $ - $ 44,742 Change in fair value (15,676) - (15,676) Cashless warrants exercise (521) - (521) Warrants exercised for cash (264) - (264) Redeemable security settlement (299) - (299) Balance – December 31, 2015 27,982 - 27,982 Extinguishment of derivative liabilities related to Cognate (10,131) (10,131) Extinguishment of warrant liabilities related to warrants exercised for cash (415) (415) Warrants granted 5,317 5,317 Share-settled debt assumed from Cognate - 5,680 5,680 Conversion of share-settled debt - (480) (480) Change in fair value (17,891) - (17,891) Balance – December 31, 2016 $ 4,862 $ 5,200 $ 10,062 A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the years ended December 31, 2016 and 2015 is as follows: Date of valuation December 31, 2016 December 31, 2015 Strike price $ 0.60 $ 3.49 Contractual term (years) 4.7 3.1 Volatility (annual) 98 % 87 % Risk-free rate 2 % 1 % Dividend yield (per share) 0 % 0 %

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5. Share-based Compensation Related Party The Company recorded approximately $ 13.6 40.8 for the year ended December 31, 2016 and 2015, respectively (see FN9). The Company issued 175,000 318,116 86,000 2.7 Other The Company issued 75,000 85,228 41,000 0.7

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment December 31, December 31, 2016 2015 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 626 598 720 692 Less: accumulated depreciation (405) (216) Total property, plant and equipment, net 315 476 Construction in progress (property in the United Kingdom)* 44,559 45,681 $ 44,874 $ 46,157 * Construction in progress includes both the land acquisition costs and the building costs. Depreciation expense was approximately $ 189,000 56,000

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. Notes Payable Remaining Stated Conversion Remaining Deferred Carrying Maturity Date Interest Rate Price Face Value Debt Discount Financing Cost Value 6% unsecured (1) 3/25/2011 & 9/19/2011 6 % $ 3.09 $ 135 $ - $ - $ 135 10% unsecured note to related party On Demand 10 % N/A 50 - - 50 12% unsecured note to related party (2) On Demand 12 % N/A 260 - - 260 2014 Senior convertible notes 8/15/2017 5 % $ 6.60 11,000 - (175) 10,825 10% unsecured (3) 11/4/2017 10 % N/A 2,450 - - 2,450 8% unsecured note (4) 6/30/2018 8 % N/A 3,310 (310) - 3,000 Share-settled debt, at fair value (5) In Default 18 % $ 0.35 5,200 - - 5,200 Mortgage loan (6) 11/16/2017 & 8/16/2017 12 % N/A 10,156 - (365) 9,791 Ending balance as of December 31, 2016 $ 32,561 $ (310) $ (540) $ 31,711 Remaining Stated Conversion Deferred Carrying Maturity Date Interest Rate Price Face Value Financing Cost Value 15% unsecured - in dispute 7/31/2011 15 % N/A $ 934 $ - $ 934 6% unsecured 3/25/2011 & 9/19/2011 6 % $ 3.09 135 - 135 10% unsecured note to related party On Demand 10 % N/A 50 - 50 2014 Senior convertible notes 8/15/2017 5 % $ 6.60 11,000 (457) 10,543 Mortgage loan 11/16/2017 & 8/16/2017 12 % N/A 11,612 (468) 11,144 Ending balance as of December 31, 2015 $ 23,731 $ (925) $ 22,806 (1) This $ 135,000 110,000 25,000 (2) On November 28, 2016, Leslie J. Goldman loaned the Company $ 260,000 12 5 (3) On November 4, 2016, the Company entered into three promissory notes agreement (“the Notes”) with an individual investor for an aggregate amount of $ 2.45 10 1 (4) On December 30, 2016, the Company entered into a note purchase agreement (the “Note”) with an individual investor for an aggregate principal amount of $ 3,310,000 8 18 300,000 10,000 (5) On October 13, 2016, the Company entered an Assignment and Assumption Agreement (the “Agreement”) with Cognate to assume certain Collateralized Full Recourse Redeemable Notes (the “Notes”) owed by Cognate for total $ 5.7 18 1,000,000 480,000 5.2 0.2 These Notes settle by providing the debt holder with a variable number of the Company’s shares with an aggregate fair value determined by reference to the debt principal outstanding. Because the value that the holder receives at settlement does not vary with the value of the Company’s equity shares, the settlement provision is not considered a conversion option for financial accounting purposes. Rather, these Notes are recognized as share-settled debt at fair value. The share-settled debt is currently in default. (6) On August 17, 2016 and November 17, 2016, the Mortgage loan lender issued two automatic one-year extensions of mortgage loan maturity date to August 16, 2017 November 16, 2017 0.2 0.3 For the years ended December 31, 2016 2015 Interest expenses related to senior convertible notes: Contractual interest $ 551 $ 640 Accelerated interest due to the conversion of convertible senior notes into common stock - 763 Amortization of debt issuance costs 282 363 Accelerated amortization of debt issuance cost due to the conversion of convertible senior notes into common stock - 302 Total interest expenses related to senior convertible notes 833 2,068 Interest expenses related to other notes: 15% unsecured originally due July 2011 - in dispute 860 140 10% unsecured notes due November 2017 57 - 6% unsecured 7 (70) 10% unsecured note due 2014 (related party) - on demand 25 18 12% unsecured note (related party) - on demand 3 - Share-settled debt, at fair value (in default) 200 - Amortization of debt discount - 57 Total interest expenses related to other notes 1,152 145 Interest expenses related to mortgage loan: Contractual interest 1,259 1,349 Amortization of debt issuance costs 568 582 Total interest expenses on the mortgage loan 1,827 1,931 Other interest expenses 6 9 Total interest expenses $ 3,818 $ 4,153

Net Loss per Share Applicable t

Net Loss per Share Applicable to Common Stockholders	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	8. Net Loss per Share Applicable to Common Stockholders Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. For the years ended December 31, 2016 2015 Common stock options 1,551 1,551 Common stock warrants - equity treatment 38,241 14,834 Common stock warrants - liability treatment 20,037 12,433 Share-settled debt and accrued interest, at fair value 15,429 - Convertible notes and accrued interest 1,766 1,763 Potentially dilutive securities 77,024 30,581

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions Cognate BioServices, Inc. The Company and Cognate BioServices entered into a DCVax-L Manufacturing Services Agreement and a DCVax-Direct Manufacturing Services Agreement, both effective January 17, 2014, and those Agreements followed and superseded Manufacturing Services Agreements in 2011 and 2007. The 2007 and 2011 Agreements had provided for baseline charges to the Company per month for dedicated manufacturing capacity, and the 2014 DCVax-L and DCVax-Direct Manufacturing Services Agreements also provide for such baseline charges. These minimum charges reflect the fact that the manufacturing suites and capacity that are going to be used for production of the Company’s DCVax products must be dedicated exclusively to the DCVax products and cannot be used to produce numerous different clients’ products in batches on a “campaign” basis, as is usually the case in contract manufacturing facilities. See description in Note 1 above. The capacity charges in the DCVax-L and DCVax-Direct Agreements entered into in January 2014 were increased in connection with the expansion of DCVax-L and DCVax-Direct production needed for the Company’s growing programs and requested by the Company. The 2007 and 2011 Agreements also contained certain provisions for fees in the event that the Company shuts down or suspends its DCVax-L clinical trial program during the Term of the Agreement. Under the April 2011 Agreement, the Company was contingently obligated to pay a $ 2 Under the January 17, 2014 DCVax®-L Manufacturing Services Agreement and the DCVax-Direct Agreement, a new set of provisions apply going forward to any shut down or suspension. Under these provisions, the Company will be contingently obligated to pay certain fees to Cognate BioServices (in addition to any other remedies) if the Company shuts down or suspends its DCVax-L program or DCVax-Direct program. For a shut down or suspension of the DCVax-L program, the fees will be as fol l ⋅ Prior to the last dose of the last patient enrolled in the Phase III trial for DCVax®-L or After the last dose of the last patient enrolled in the Phase III clinical trial for DCVax®-L but before any submission for product approval in any jurisdiction or after the submission of any application for market authorization but prior to receiving a marketing authorization approval: in any of these cases, the fee shall be $ 3 ⋅ At any time after receiving the equivalent of a marketing authorization for DCVax®-L in any jurisdiction, the fee shall be $ 5 For a shut down or suspension of the DCVax-Direct program, the fees will be as follows: ⋅ Prior to the last dose of the last patient enrolled in the Phase I/II trial for DCVax®-Direct, the fee shall be $ 1.5 ⋅ After the last dose of the last patient enrolled in the Phase I/II clinical trial for DCVax®-Direct but before the initiation of a Phase III trial the fee shall be $ 2.0 ⋅ After initiation of a phase III trial but before submission of an application for market authorization in any jurisdiction or after the submission of an application for market authorization but prior to receiving a market authorization approval: in each of these cases, the fee shall be $ 3.0 ⋅ At any time after receiving the equivalent of a marketing authorization for DCVax®-Direct in any jurisdiction the fee shall be $ 5.0 While our DCVax programs are ongoing, the Company is required to pay certain fees for dedicated production suites or capacity reserved exclusively for DCVax production, and pay for a certain minimum number of patients, whether or not we fully utilize the dedicated capacity and number of patients. Remediation Plan As previously reported, on April 26, 2016, the Nasdaq Staff notified the Company that it had reviewed certain stock issuances by the Company to Cognate during 2014 and 2015, and that the Staff had determined that those issuances should be aggregated for purposes of applying Nasdaq rules. Under Nasdaq rules, for purposes of measuring against the limit of 20 The Company proposed a remediation plan (the “Remediation Plan”) that Cognate would surrender certain shares and warrants it had received in connection with the Contracts, Cognate would accept an increase in the exercise price of certain warrants received in connection with the Contracts, and the most favored nation anti-dilution provisions would be deleted from the Contracts. The Remediation Plan was accepted by the Nasdaq staff on August 30, 2016. Pursuant to the Remediation Plan: (a) Cognate returned and the Company canceled 8,052,092 (b) Cognate returned and the Company canceled warrants for 6,880,574 4,305,772 4.27 5 (c) Cognate returned and the Company canceled 731,980 5,101,330 The remaining portions of the multi-year lock-up and vesting periods relating to shares and warrants held by Cognate were also cancelled. The Nasdaq settlement does not affect other obligations of the Company to Cognate, including for existing unpaid invoices, as the Company has previously reported. Cognate Expenses and Accounts Payable As of December 31, 2016 and 2015, the Company owed Cognate $ 23.4 5.5 For the years ended December 31, 2016 2015 Cognate research and development cost - services $ 34,665 $ 37,703 Stock issued to and returned by Cognate 13,654 40,765 Total $ 48,319 $ 78,468 Share Based Payments Fiscal 2016 Activities On September 7, 2016, under the Company’s Remediation Agreement with Nasdaq, Cognate returned 8,052,092 731,980 731,980 731,980 221,000 Fiscal 2015 Activities For the year ended December 31, 2015, the Company issued 318,116 2.7 On October 19, 2015, the Company issued 8,052,092 38.8 3 On October 19, 2015, the Company also approved the issuance of 3,812,555 On October 22, 2015, 681,884 3.8 The Company recorded approximately $ 13.6 40.8 on the date of issuance Shares payable to related party - elimination of most favored nation provision Shares and warrants previously issued to Cognate in partial payment of invoices for manufacturing services were under a 3-year lock-up, which had been in place since January 2014. The lock-up prevented Cognate from selling the shares received. During the lock-up, if the Company entered into a transaction with other investors or creditors on more favorable terms than Cognate received, the Company had an ongoing obligation, under the Manufacturing Services Agreements, to conform the terms of Cognate’s shares and warrants to the same terms as the other investors or creditors, under a most favored nation provision. During the nine months period ended September 30, 2016, the Company entered into several financings with unrelated institutional investors that triggered the most favored nation provision. However, these most favored nation shares were never issued to Cognate. Under the Remediation Agreement, Cognate agreed to eliminate the most favored nation provisions, and to forego these shares that had already been triggered. As a result of the elimination of the most favored nation, the Company reclassified $ 22.5 Letter Agreement and Assignment Agreement with Related Party The Company entered into a Letter Agreement (the “Agreement”) with Cognate and related agreements in connection with an institutional financing of Cognate and to enable the Company to continue obtaining services from Cognate for the Company’s ongoing Phase III DCVax®-L trial and upcoming Phase II DCVax®-Direct trials. As an initial implementation step pursuant to the Agreement, on October 13, 2016 the Company entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) pursuant to which the Company agreed to assume certain Cognate debt obligations in connection with preparations for initiation of Phase II clinical trials and further services in ongoing trials. The Company and Cognate are in negotiations in regard to crediting of the assumed debt against a portion of the unpaid invoices owed by the Company to Cognate. The terms for the crediting have not yet been finalized. As further consideration for Cognate's forbearance described above, in the future, when and if permitted, the Company will reverse the conversion of $ 3.75 30,000 As previously reported, the Company has also been negotiating with the third party lender in regard to the assumed debt. Based on discussions to date, the Company anticipates that, over a period of up to one year, the obligations could total an amount up to approximately $ 5 480,000 1,000,000 0.48 Cognate Organization Pursuant to an institutional financing of Cognate in October 2016, Cognate’s operations outside the US were separated from its operations in the US. The operations outside the US include Cognate BioServices GmbH in Germany, Cognate BioServices Ltd. In the UK, and Cognate Israel in Israel. Both Cognate BioServices, Inc. in the US and the Cognate affiliates outside the US are owned by Toucan Fund III. The Cognate affiliate in Germany works with the Fraunhofer Institute to produce DCVax-L products there, and Cognate affiliates in the UK and Israel are preparing for production of DCVax-L products in those locations. Approximately $ 4.3 Other Related Parties Jerry Jasinowski – Private Offering On December 22, 2016, the Company issued 1,285,714 0.35 642,857 0.35 450,000 Leslie J. Goldman – Demand Loan On November 28, 2016, Leslie J. Goldman, an officer of the Company, loaned the Company $ 260,000 12 On October 8, 2015, Leslie J. Goldman, an officer of the Company, loaned the Company $ 400,000 8 35 403,858 28,384 5 4.98

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity (Deficit) Common Stock Issuances First Quarter of 2016 On February 29, 2016, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain institutional investors (the “Purchasers”), for a registered direct offering (the “Offering”) of 5,882,353 1.70 2,941,177 2.25 In addition, the Company granted the Purchasers a sixty (60) day overallotment option in the form of Series B Warrants to purchase an additional 5,882,353 3.00 10 9.2 Each Purchaser also received Series C Warrants (the “Series C Warrants”) to purchase up to 2,941,177 4.00 In connection with the Offering and the concurrent private placement, the Company agreed to pay the Placement Agent a cash placement fee equal to 7 294,118 5 2.125 125 Second Quarter of 2016 On May 15, 2016, the Company entered into an agreement with a holder (the “Holder”) of the Company’s existing Series A, B and C Warrants, pursuant to which the Holder agreed to exercise all of the Holder’s Series B Warrants to purchase 4,411,764 0.96 4,235 2,205,882 1.00 The Holder’s exercise of the Series B Warrants to purchase 4,411,764 2,205,882 1.00 In connection with the offering and the concurrent private placement, the Company agreed to pay the Placement Agent a cash placement fee equal to 7 220,588 5 1.20 125 The modification of the warrant exercise price increased the value of the warrants by approximately $ 2.6 Third Quarter of 2016 During the quarter ended September 30, 2016, the Company issued 7,400,000 0.50 3,700,000 0.60 3.4 321 During the quarter ended September 30, 2016, the Company entered into multiple agreements with certain holders (the “Holders”) of the Company’s existing warrants, pursuant to which the Holders agreed to exercise all of the Holders’ warrants to purchase 10,945,694 0.35 3.4 454,000 0.44 5 263,122 0.44 The modification of the warrant exercise price increased the value of the warrants by approximately $ 3.0 During the quarter ended September 30, 2016, the Company issued a total of 2,572,216 0.36 0.9 1,286,111 0.42 5 On September 16, 2016, the Company converted a note in dispute and relevant accrued interest of $ 1.0 2,222,222 1,111,111 0.45 5 0.4 0.4 Fourth Quarter of 2016 During the quarter ended December 31, 2016, the Company issued 28,575,000 0.35 14,287,500 0.35 9.2 0.8 In October 2016 and November 2016, the Company issued a total of 2,518,687 0.53 1.3 1,259,345 0.51 5 On December 22, 2016, the Company issued 1,285,714 0.35 642,857 0.35 450,000 Total warrants issued from direct offerings and private placement have value of approximately $ 4.2 During the quarter ended December 31, 2016, the Company issued a total of 60,000 0.49 29,400 During the quarter ended December 31, 2016, the Company converted accrued interest associated with a note in dispute that was originally issued in 2011. The accrued interest balance as of December 13, 2016 was $ 1.5 2,812,174 1,406,086 0.50 5 1.5 0.6 The total loss on the extinguishment of accrued interest was approximately $ 0.7 During the quarter ended December 31, 2016, the Company issued 1,000,000 480,000 First Quarter 2015 During the quarter ended March 31, 2015, the Company issued an aggregate of 888,187 3.7 During the quarter ended March 31, 2015, the Company issued 80,068 0.3 During the quarter ended March 31, 2015, the Company issued an aggregate of 385,000 0.5 Second Quarter 2015 On April 2, 2015, the Company entered into a stock purchase agreement (the “Agreement”) with Woodford Investment Management LLP as agent for the CF Woodford Equity Income Fund and other clients (collectively, “Woodford”). Pursuant to the Agreement, the Company agreed to sell, and Woodford agreed to purchase, 5,405,405 0.001 7.40 40 1,554,054 11.5 April 8, 2015 3,851,351 28.5 May 1, 2015 During the quarter ended June 30, 2015, the Company converted $ 4.5 701,033 During the quarter ended June 30, 2015, the Company issued an aggregate of 723,422 3.1 9,200 0.06 During the quarter ended June 30, 2015, the Company issued an aggregate of 183,895 During the quarter ended June 30, 2015, the Company issued an aggregate of 85,228 0.7 During the quarter ended June 30, 2015, the Company issued an aggregate of 318,116 8.1 Third Quarter 2015 During the quarter ended September 30, 2015, the Company issued an aggregate of 116,675 0.8 57,500 0.2 During the quarter ended September 30, 2015, the Company issued an aggregate of 2,566 During the quarter ended September 30, 2015, the Company converted $ 2 322,502 Fourth Quarter 2015 Effective October 2015, the Company entered into a stock purchase agreement (the “Agreement”) with Woodford Investment Management LLP as agent for the CF Woodford Equity Income Fund and other clients (collectively, “Woodford”). Pursuant to the Agreement, the Company issued 5,454,545 0.001 5.50 30 Additionally, in connection with the Woodford Financing, the Company issued 681,884 3.8 On October 19, 2015, the Company issued 8,052,092 38.8 On December 22, 2015, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain healthcare-focused institutional investors (the “Purchasers”), for a registered direct offering (the “Offering”) of 3,500,000 0.001 3.60 1,750,000 4.50 12.6 11.65 Stock Purchase Warrants Number of Weighted Average Warrants Exercise Price Outstanding as of January 1, 2015 29,385 $ 4.72 Warrants granted 1,953 4.51 Warrants exercised for cash (1,678) 4.25 Warrants exercised on a cashless basis* (304) 3.96 Warrant adjustment due to Cognate price reset 62 3.35 Warrants expired and cancellation (2,431) 4.82 Adjustment related to prior issued warrants 280 4.41 Outstanding as of December 31, 2015 ** 27,267 4.40 Warrants granted in a registered direct offering 14,485 2.70 Warrants granted to Cognate* 35,504 0.69 Warrants canceled by Cognate (37,147) 0.35 Warrants exercised for cash (15,357) 0.53 Warrants granted *** 35,287 0.43 Warrants expired and cancellation (1,761) 9.36 Outstanding as of December 31, 2016** 58,278 $ 1.78 * The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period. ** Approximately 49,827,000 37,147,000 4.19 2.43 *** According to the sequencing policy (FN3), the Company classifies these derivative warrant liabilities on the consolidated balance sheet as a

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Variable Interest Entity Disclosure [Text Block]	11. Variable Interest Entities Variable Interest Entities (“VIEs”) are entities in which equity investors lack the characteristics of a controlling financial interest. VIEs are consolidated by the primary beneficiary. The primary beneficiary is the party who has both the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. After the assumption of $ 5.7 3.8 The maximum exposure to loss is limited to the notional amounts of the implicit variable interest in Cognate. The Company has no current plans to provide any support additional to that which is noted above. Therefore, the maximum exposure to loss from its implicit interest is limited to $ 4.5 ; which is the shutdown fee the Company must pay to terminate their relationship with Cognate

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies Contingent Payment to Cognate BioServices Under the January 17, 2014 DCVax®-L Manufacturing Services Agreement and the DCVax-Direct Agreement, a new set of provisions apply going forward to any shut down or suspension. Under these provisions, the Company will be contingently obligated to pay certain fees to Cognate BioServices (in addition to any other remedies) if the Company shuts down or suspends its DCVax-L program or DCVax-Direct program. For a shut down or suspension of the DCVax-L program, the fees will be as fol l · Prior to the last dose of the last patient enrolled in the Phase III trial for DCVax®-L or After the last dose of the last patient enrolled in the Phase III clinical trial for DCVax®-L but before any submission for product approval in any jurisdiction or after the submission of any application for market authorization but prior to receiving a marketing authorization approval: in any of these cases, the fee shall be $ 3 · At any time after receiving the equivalent of a marketing authorization for DCVax®-L in any jurisdiction, the fee shall be $ 5 For a shut down or suspension of the DCVax-Direct program, the fees will be as follows: · Prior to the last dose of the last patient enrolled in the Phase I/II trial for DCVax®-Direct, the fee shall be $ 1.5 · After the last dose of the last patient enrolled in the Phase I/II clinical trial for DCVax®-Direct but before the initiation of a Phase III trial the fee shall be $ 2.0 · After initiation of a phase III trial but before submission of an application for market authorization in any jurisdiction or after the submission of an application for market authorization but prior to receiving a market authorization approval: in each of these cases, the fee shall be $ 3.0 · At any time after receiving the equivalent of a marketing authorization for DCVax®-Direct in any jurisdiction the fee shall be $ 5.0 While our DCVax programs are ongoing, the Company is required to pay certain fees for dedicated production suites or capacity reserved exclusively for DCVax production, and pay for a certain minimum number of patients, whether or not we fully utilize the dedicated capacity and number of patients. Operating Lease On July 31, 2012, the Company entered into a non-cancelable operating lease for 7,097 square feet 0.3 0.3 On October 28, 2013, the Company entered into a non-cancelable operating lease for 4,251 square feet On March 26, 2016, the Company entered into a non-cancelable operating lease for 505 square feet 120,000 Office Leases U.S. Germany U.K. Total 2017 $ 318 $ 64 $ 175 $ 557 2018 81 - 39 120 Total $ 399 $ 64 $ 214 $ 677 Derivative and Class Action Litigation On June 19, 2015, two purported shareholders filed a lawsuit in the Delaware Court of Chancery, captioned Tharp, et al. v. Cognate, et al. On November 19, 2015, a third purported shareholder filed a lawsuit in the U.S. District Court for the District of Maryland, captioned Yonemura v. Powers, et al. On November 28, 2016, a purported shareholder filed a lawsuit in the Circuit Court for Montgomery County, Maryland, captioned Wells v. Powers, et al. Class Action Securities Litigation On August 26, 2015, a purported shareholder of the Company filed a putative class action lawsuit in the U.S. District Court for the District of Maryland, captioned Lerner v. Northwest Biotherapeutics, Inc. Shareholder Books and Record Demand On December 7, 2015, the Company received a letter on behalf of shareholders demanding to inspect certain corporate books and records pursuant to Section 220 of the Delaware General Corporation Law. The demand letter claimed that its purpose was to investigate: (1) allegedly improper transactions, misconduct, and mismanagement by directors and an officer of the Company; (2) the possible breach of fiduciary duty by certain directors and officers of the Company; and (3) the independence and disinterestedness of the Company’s board, to determine whether a pre-suit demand would be necessary before commencing any derivative action on behalf of the Company. U.S. Securities and Exchange Commission As previously reported, on December 13, 2016, the Company received a formal information request (subpoena) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, internal controls and the Company’s Special Litigation Committee. The period covered is January 1, 2013 to the present. The investigation is ongoing and the Company is cooperating fully. Special Litigation Committee As previously reported, the Company appointed a Special Litigation Committee, and Committee has undertaken an inquiry into the allegations of various lawsuits filed against the Company, and an anonymous internet report raising a number of criticisms of the Company and its Board and management, including with respect to the reasonableness of the transactions with Cognate. The Committee has retained experts to analyze some of these issues.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. Income Taxes No provision was made for U.S. taxes on undistributed foreign earning as such earnings are considered to be permanently reinvested. It is not practicable to determine the amount of additional tax, if any that might be payable on those earnings if repatriated. As of December 31, 2016 2015 Deferred tax asset Net operating loss carryforward $ 204,106 $ 180,927 Research and development credit carry forwards 14,911 12,661 Stock based compensation and other 17,106 24,759 Total deferred tax assets 236,123 218,347 Valuation Allowance (236,123) (218,347) Deferred tax asset, net of allowance $ - $ - The Company has identified the United States, Maryland, Germany and United Kingdom as significant tax jurisdictions. At December 31, 2016, the Company had Federal and State net operating loss carry forwards for income tax purposes of 507.5 14.9 2036. The Company has foreign net operating loss carry forwards of $ 17.7 During 2016 the Company reevaluated the pricing/deductibility of stock options granted and the value of warrants issued, resulting in the decrease in the potential future tax deduction from those instruments. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2016 and 2015. (dollars in thousands) For the years ended 2016 2015 Statutory federal income tax rate 34.0 % 34.0 % State taxes, net of federal tax benefit 1.8 % 5.4 % Tax rate differential on foreign income -2.3 % 0.0 % Derivative gain or loss and other 7.6 % 5.8 % Cancellation of shares -16.6 % 0.0 % Cancellation of warrants -7.8 % 0.0 % Other permanent items and true ups 2.7 % 0.0 % R&D Credit 2.8 % 2.6 % Change in valuation allowance -22.2 % -47.8 % Income tax provision (benefit) 0.0 % 0.0 % For the years ended 2016 2015 Federal Current $ - $ - Deferred (11,160) (41,583) State Current - - Deferred (1,427) (6,659) Foreign Current - - Deferred (5,189) - Change in valuation allowance 17,776 48,242 Income tax provision (benefit) $ - $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	14. Subsequent Events Registered Direct Offering On March 17, 2017, the Company entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $ 7.5 18.8 0.26 21.6 0.26 21.6 1.00 4.99 10.0 0.26 0.25 0.01 Debt Financing Commencing March 1, 2017, the Company entered into a series of six nonconvertible, promissory notes with unrelated third parties (the “Notes”) in the original principal amount of $ 2,020,000 3 1,959,400 15 On March 3, 2017, the Company entered into an additional nonconvertible, promissory note with an unrelated third party in the original principal amount of $ 1,155,000 10 1,000,000 8 5 Debt Repurchase On March 9, 2017, the Company and certain debt holders (the “Holders”) of Convertible Senior Notes that were issued in August, 2014 (the “Notes”) signed a Note Repurchase Agreement providing for the (a) immediate payment to the Holder of $ 500,000 7 1.5 0.3713 500,000 2,000,000 2,000,000 2,500,000 2,500,000 5,500,000 5,500,000 payment, when any cumulative financing of new cash during the period of the Note Repurchase Agreement exceeds $15 million, of 30% of such excess amount to repurchase Notes from the Holders within three business days of the closing of any such raise. Debt Conversion On March 30, 2017, the Company issued 2,500,000 0.001

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany and the United Kingdom. All intercompany transactions and accounts have been eliminated in consolidation.
Consolidation, Policy [Policy Text Block]	Consolidation The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities which meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE.
Reclassification, Policy [Policy Text Block]	Prior Period Reclassifications Certain prior period amounts that were combined in the December 31, 2015 consolidated financial statements have been reclassified for comparability with the December 31, 2016 presentation. These reclassifications had no effect on previously reported net loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash consists of funds deposited in checking accounts. The Company has them either in a form of bank deposits or highly liquid debt instruments in investment-grade pursuant to the Company's investment policy. Accounts at each institution are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $ 250,000 5.8
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash The Company records cash held in an escrow account to secure certain debt interest obligations as restricted cash. As of December 31, 2016 and 2015, the Company has $ 0.7 1.2
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. For more details see Note 6. The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amounts or fair value less cost to sell. Management determines fair value using the discounted cash flow method or other accepted valuation techniques. Accordingly, during the year ended December 31, 2016, an assessment was undertaken to determine whether $ 44.6 The Company’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered, and therefore there was no impairment as of December 31, 2016. Of course, it is possible that the estimate of undiscounted cash flows could change at some time in the future, resulting in a need at that time to write down such assets to fair value.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply, and the fair value of environmental remediation liabilities.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The carrying amount of the Company’s financial instruments, including cash and cash equivalents and accounts payable approximate their fair values. As of December 31, 2016, the carrying amount of the notes payable approximate fair value as its interest rate approximates current market rates.
Deferred Charges, Policy [Policy Text Block]	Deferred Financing Costs The Company capitalizes costs related to the issuance of debt which are included on the accompanying consolidated balance sheets. Deferred financing costs are amortized using a straight-line method that approximates the interest method over the life of the related loan and are included as a component of interest expense on the accompanying consolidated statements of operations.
Warrant Liability Policy [Policy Text Block]	Warrant Liability The Company accounts for the common stock warrants outstanding as of December 31, 2016 in accordance with the guidance contained in ASC 815-40-15-7D, "Contracts in Entity's Own Equity" whereby under that provision they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company in connection with the Conversion Transaction has been estimated using a Monte Carlo simulation. In addition, Under ASC 815, registered common stock warrants that require the issuance of registered shares upon exercise and do not expressly preclude an implied right to cash settlement are accounted for as derivative liabilities. The Company classifies these derivative warrant liabilities on the consolidated balance sheet as a current liability.
Environmental Cost, Expense Policy [Policy Text Block]	Environmental Remediation Liabilities The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The reduction in the liability resulting from the completion of the clean-up is included in other income. As of December 31, 2016, the Company estimate that the total environmental remediation costs associated with the purchase of the UK Facility will amount to approximately $ 6.2 6.2 4.5 32.0
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation and Transactions The Company has operations in Germany and the United Kingdom in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity (deficit). During the year ended December 31, 2016, the Company recorded $ 2.0 During the year ended December 31, 2016, the Company also recorded $ 6.7
Comprehensive Loss Policy [Policy Text Block]	Comprehensive Loss The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, is excluded from net loss.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. Due to potential collectability issues with patients, the Company has adopted a policy of recognizing these payments as revenue when received.
Accrued Outsourcing Costs [Policy Text Block]	Accrued Outsourcing Costs Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively "CROs"). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs. Research and development costs were approximately $ 60.1 103.1
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes income taxes on an accrual basis based on tax positions taken or expected to be taken in its tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however prior to 1998 the Company was a limited liability company and the Company’s tax losses and credits generally flowed directly to the members.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Non-Employee Stock Based Compensation Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. The Company estimates pre-vesting option forfeitures at the time of grant and reflects the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. The Company accounts for stock based compensation awards issued to non-employees for services, at either the fair value of the services or the instruments issued in exchange for such services (based on the same methodology described for employee stock based compensation), whichever is more readily determinable.
Extinguishment Of Debt [Policy Text Block]	The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished should be recognized as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under "other income (expense)" as loss from extinguishment of convertible debt.
Debt, Policy [Policy Text Block]	Share-settled Debt Share-settled debt may settle by providing the holder with a variable number of shares with an aggregate fair value equaling the debt principal outstanding. (In some cases, a discount to the fair value of the share price may be used to determine the number of shares to be delivered, resulting in settlement at a premium.) Share-settled debt was analyzed to determine that the share settled debt does not contain a beneficial conversion feature or contingent beneficial conversion feature. Share-settled debt is recorded at fair value.
Sequencing [Policy Text Block]	As of October 13, 2016, the Company adopted a sequencing policy whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.
Earnings Per Share, Policy [Policy Text Block]	Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares (including redeemable shares) plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.
Operating Segments [Policy Text Block]	Segments The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented herein.
Significant Accounting Policies [Policy Text Block]	Adoption of Recent Accounting Pronouncements Going Concern In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-15, “Presentation of Financial Statements - Going Concern”, which provide guidance about management's responsibility in evaluating whether there is substantial doubt relating to an entity’s ability to continue as a going concern and to provide related footnote disclosures as applicable. ASU 2014-15 is effective for the interim and annual periods ending after December 15, 2016 and the Company adopted the provisions of ASU 2014-15 as of December 31, 2016. There was no impact from adoption of this guidance on the Company's consolidated financial statements. Interest - Imputation of Interest In August 2015, the FASB issued ASU No. 2015-15, “Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the treatment of debt issuance costs from line-of-credit arrangements after the adoption of ASU No. 2015-03, “Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. In particular, ASU No. 2015-15 clarifies that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to a line-of-credit arrangement as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of such arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted ASU No. 2015-15 during the first quarter of fiscal 2016, and its adoption did not have a material impact on its consolidated financial statements. Restricted Cash In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 during the three months ended December 31, 2016 on a retrospective basis. As a result, net cash provided by operating activities increased by $ 1.1 1.2 December 31, 2016 December 31, 2015 Cash and cash equivalents $ 6,186 $ 21,813 Restricted cash 685 1,235 Total cash and restricted cash $ 6,871 $ 23,048
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Statement of Cash Flows In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which addresses specific cash flow classification issues where there is currently diversity in practice including debt prepayment and proceeds from the settlement of insurance claims. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently assessing the impact that ASU No. 2016-15 will have on its consolidated financial statements. Compensation-Stock Compensation In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting Revenue from Contracts with Customer In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, an updated standard on revenue recognition. ASU No. 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU No. 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. The Company is currently evaluating the pending adoption of ASU 2014-09 and its impact on the Company's consolidated financial statements and has not yet identified which transition method will be applied upon adoption. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customer Recognition and Measurement of Financial Assets and Financial Liabilities In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities Leases In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840)

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Cash, Cash Equivalents and Investments [Table Text Block]	The following is a summary of our cash and restricted cash total as presented in the consolidated statements of cash flows for the years ended December 31, 2016 and 2015 (in thousands): December 31, 2016 December 31, 2015 Cash and cash equivalents $ 6,186 $ 21,813 Restricted cash 685 1,235 Total cash and restricted cash $ 6,871 $ 23,048

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair value measured at December 31, 2016 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2016 (Level 1) (Level 2) (Level 3) Derivative liability $ 4,862 $ - $ - $ 4,862 Share-settled debt (in default) 5,200 5,200 Total fair value $ 10,062 $ - $ - $ 10,062 Fair value measured at December 31, 2015 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Derivative liability $ 27,982 $ - $ - $ 27,982
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands). Warrant Share-settled Liability Debt (in Default) Total Balance – January 1, 2015 $ 44,742 $ - $ 44,742 Change in fair value (15,676) - (15,676) Cashless warrants exercise (521) - (521) Warrants exercised for cash (264) - (264) Redeemable security settlement (299) - (299) Balance – December 31, 2015 27,982 - 27,982 Extinguishment of derivative liabilities related to Cognate (10,131) (10,131) Extinguishment of warrant liabilities related to warrants exercised for cash (415) (415) Warrants granted 5,317 5,317 Share-settled debt assumed from Cognate - 5,680 5,680 Conversion of share-settled debt - (480) (480) Change in fair value (17,891) - (17,891) Balance – December 31, 2016 $ 4,862 $ 5,200 $ 10,062
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the years ended December 31, 2016 and 2015 is as follows: Date of valuation December 31, 2016 December 31, 2015 Strike price $ 0.60 $ 3.49 Contractual term (years) 4.7 3.1 Volatility (annual) 98 % 87 % Risk-free rate 2 % 1 % Dividend yield (per share) 0 % 0 %
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	During the year ended December 31, 2016 approximately 2,555,000 2016 Warrants Exercises Strike price $ 0.35 Contractual term (years) 2.2 Volatility (annual) 84 % Risk-free rate 1 % Dividend yield (per share) 0 %
Cognate Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Cognate warrants extinguishment as of August 30, 2016 is as follows: Date of valuation August 30, 2016 Strike price $ 0.35 Contractual term (years) 2.8 Volatility (annual) 81 % Risk-free rate 1 % Dividend yield (per share) 0 %
Derivative Warrants [Member] | Debt Conversion [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring warrant granted during the year ended December 31, 2016 is as follows: 2016 Warrants Granted Strike price $ 0.48 Contractual term (years) 5.5 Volatility (annual) 137 % Risk-free rate 1 % Dividend yield (per share) 0 %
Derivative Warrants [Member] | Public and Private Offering [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring warrant granted during the year ended December 31, 2016 is as follows: 2016 Warrants Granted Strike price $ 0.36 Contractual term (years) 5.0 Volatility (annual) 99 % Risk-free rate 2 % Dividend yield (per share) 0 %

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	December 31, December 31, 2016 2015 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 626 598 720 692 Less: accumulated depreciation (405) (216) Total property, plant and equipment, net 315 476 Construction in progress (property in the United Kingdom)* 44,559 45,681 $ 44,874 $ 46,157 * Construction in progress includes both the land acquisition costs and the building costs.

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of Debt [Table Text Block]	The following table summarizes outstanding debt as of December 31, 2016 and 2015, respectively (amount in thousands): Remaining Stated Conversion Remaining Deferred Carrying Maturity Date Interest Rate Price Face Value Debt Discount Financing Cost Value 6% unsecured (1) 3/25/2011 & 9/19/2011 6 % $ 3.09 $ 135 $ - $ - $ 135 10% unsecured note to related party On Demand 10 % N/A 50 - - 50 12% unsecured note to related party (2) On Demand 12 % N/A 260 - - 260 2014 Senior convertible notes 8/15/2017 5 % $ 6.60 11,000 - (175) 10,825 10% unsecured (3) 11/4/2017 10 % N/A 2,450 - - 2,450 8% unsecured note (4) 6/30/2018 8 % N/A 3,310 (310) - 3,000 Share-settled debt, at fair value (5) In Default 18 % $ 0.35 5,200 - - 5,200 Mortgage loan (6) 11/16/2017 & 8/16/2017 12 % N/A 10,156 - (365) 9,791 Ending balance as of December 31, 2016 $ 32,561 $ (310) $ (540) $ 31,711 Remaining Stated Conversion Deferred Carrying Maturity Date Interest Rate Price Face Value Financing Cost Value 15% unsecured - in dispute 7/31/2011 15 % N/A $ 934 $ - $ 934 6% unsecured 3/25/2011 & 9/19/2011 6 % $ 3.09 135 - 135 10% unsecured note to related party On Demand 10 % N/A 50 - 50 2014 Senior convertible notes 8/15/2017 5 % $ 6.60 11,000 (457) 10,543 Mortgage loan 11/16/2017 & 8/16/2017 12 % N/A 11,612 (468) 11,144 Ending balance as of December 31, 2015 $ 23,731 $ (925) $ 22,806 (1) This $ 135,000 110,000 25,000 (2) On November 28, 2016, Leslie J. Goldman loaned the Company $ 260,000 12 5 (3) On November 4, 2016, the Company entered into three promissory notes agreement (“the Notes”) with an individual investor for an aggregate amount of $ 2.45 10 1 (4) On December 30, 2016, the Company entered into a note purchase agreement (the “Note”) with an individual investor for an aggregate principal amount of $ 3,310,000 8 18 300,000 10,000 (5) On October 13, 2016, the Company entered an Assignment and Assumption Agreement (the “Agreement”) with Cognate to assume certain Collateralized Full Recourse Redeemable Notes (the “Notes”) owed by Cognate for total $ 5.7 18 1,000,000 480,000 5.2 0.2 These Notes settle by providing the debt holder with a variable number of the Company’s shares with an aggregate fair value determined by reference to the debt principal outstanding. Because the value that the holder receives at settlement does not vary with the value of the Company’s equity shares, the settlement provision is not considered a conversion option for financial accounting purposes. Rather, these Notes are recognized as share-settled debt at fair value. The share-settled debt is currently in default. (6) On August 17, 2016 and November 17, 2016, the Mortgage loan lender issued two automatic one-year extensions of mortgage loan maturity date to August 16, 2017 November 16, 2017 0.2 0.3
Interest Income and Interest Expense Disclosure [Table Text Block]	The following table summarizes total interest expenses related to senior convertible notes, share-settled debt, other notes and mortgage loan for years ended December 31, 2016 and 2015, respectively (in thousands): For the years ended December 31, 2016 2015 Interest expenses related to senior convertible notes: Contractual interest $ 551 $ 640 Accelerated interest due to the conversion of convertible senior notes into common stock - 763 Amortization of debt issuance costs 282 363 Accelerated amortization of debt issuance cost due to the conversion of convertible senior notes into common stock - 302 Total interest expenses related to senior convertible notes 833 2,068 Interest expenses related to other notes: 15% unsecured originally due July 2011 - in dispute 860 140 10% unsecured notes due November 2017 57 - 6% unsecured 7 (70) 10% unsecured note due 2014 (related party) - on demand 25 18 12% unsecured note (related party) - on demand 3 - Share-settled debt, at fair value (in default) 200 - Amortization of debt discount - 57 Total interest expenses related to other notes 1,152 145 Interest expenses related to mortgage loan: Contractual interest 1,259 1,349 Amortization of debt issuance costs 568 582 Total interest expenses on the mortgage loan 1,827 1,931 Other interest expenses 6 9 Total interest expenses $ 3,818 $ 4,153

Net Loss per Share Applicable27

Net Loss per Share Applicable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands): For the years ended December 31, 2016 2015 Common stock options 1,551 1,551 Common stock warrants - equity treatment 38,241 14,834 Common stock warrants - liability treatment 20,037 12,433 Share-settled debt and accrued interest, at fair value 15,429 - Convertible notes and accrued interest 1,766 1,763 Potentially dilutive securities 77,024 30,581

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2016
Related Party Transaction, Due from (to) Related Party [Abstract]
Research and Development Arrangement, Contract to Perform for Others [Table Text Block]	The following table shows a summary of research and development costs from Cognate relating to the DCVax-L and DCVax-Direct programs, product and process development work and preparations for upcoming Phase II trials for the years ended December 31, 2016 and 2015, respectively (in thousands): For the years ended December 31, 2016 2015 Cognate research and development cost - services $ 34,665 $ 37,703 Stock issued to and returned by Cognate 13,654 40,765 Total $ 48,319 $ 78,468

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule Of Warrant Activity [Table Text Block]	The following is a summary of warrant activity for the years ended December 31, 2016 and 2015 (dollars in thousands, except per share data): Number of Weighted Average Warrants Exercise Price Outstanding as of January 1, 2015 29,385 $ 4.72 Warrants granted 1,953 4.51 Warrants exercised for cash (1,678) 4.25 Warrants exercised on a cashless basis* (304) 3.96 Warrant adjustment due to Cognate price reset 62 3.35 Warrants expired and cancellation (2,431) 4.82 Adjustment related to prior issued warrants 280 4.41 Outstanding as of December 31, 2015 ** 27,267 4.40 Warrants granted in a registered direct offering 14,485 2.70 Warrants granted to Cognate* 35,504 0.69 Warrants canceled by Cognate (37,147) 0.35 Warrants exercised for cash (15,357) 0.53 Warrants granted *** 35,287 0.43 Warrants expired and cancellation (1,761) 9.36 Outstanding as of December 31, 2016** 58,278 $ 1.78 * The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period. ** Approximately 49,827,000 37,147,000 4.19 2.43 *** According to the sequencing policy (FN3), the Company classifies these derivative warrant liabilities on the consolidated balance sheet as a

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The Company’s future minimum lease payments are as follows as of December 31, 2016 (in thousands): Office Leases U.S. Germany U.K. Total 2017 $ 318 $ 64 $ 175 $ 557 2018 81 - 39 120 Total $ 399 $ 64 $ 214 $ 677

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2016 and 2015 are comprised of the following (in thousands): As of December 31, 2016 2015 Deferred tax asset Net operating loss carryforward $ 204,106 $ 180,927 Research and development credit carry forwards 14,911 12,661 Stock based compensation and other 17,106 24,759 Total deferred tax assets 236,123 218,347 Valuation Allowance (236,123) (218,347) Deferred tax asset, net of allowance $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	(dollars in thousands) For the years ended 2016 2015 Statutory federal income tax rate 34.0 % 34.0 % State taxes, net of federal tax benefit 1.8 % 5.4 % Tax rate differential on foreign income -2.3 % 0.0 % Derivative gain or loss and other 7.6 % 5.8 % Cancellation of shares -16.6 % 0.0 % Cancellation of warrants -7.8 % 0.0 % Other permanent items and true ups 2.7 % 0.0 % R&D Credit 2.8 % 2.6 % Change in valuation allowance -22.2 % -47.8 % Income tax provision (benefit) 0.0 % 0.0 %
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the years ended 2016 2015 Federal Current $ - $ - Deferred (11,160) (41,583) State Current - - Deferred (1,427) (6,659) Foreign Current - - Deferred (5,189) - Change in valuation allowance 17,776 48,242 Income tax provision (benefit) $ - $ -

Liquidity, Financial Conditio32

Liquidity, Financial Condition and Management Plans (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	$ (55,652)	$ (79,711)
Current Assets Less Payables	68,500
Net Income (Loss) Attributable To Parent	(80,214)	(114,741)
Accounts Payable, Related Parties, Current	23,353	5,455
Assets, Current, Total	7,884	$ 24,101
Share Based Compensation Aggregate Charges For Interest Associated With Accretion Of Our Convertible Notes Discount Net	$ 5,800

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 6,186	$ 21,813
Restricted cash	685	1,235
Total cash and restricted cash	$ 6,871	$ 23,048	$ 16,015

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary of Significant Accounting Policies [Line Items]
Accrued Environmental Loss Contingencies, Noncurrent	$ 6,200,000
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	6,200,000
Time Deposits, at or Above FDIC Insurance Limit	5,800,000
Restricted Cash and Cash Equivalents	685,000	$ 1,235,000
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	(1,971,000)	(67,000)
Research and Development Expense	60,081,000	103,120,000
Property, Plant and Equipment, Gross	720,000	692,000
Adjustments for New Accounting Pronouncement [Member]
Summary of Significant Accounting Policies [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Operating Results		$ 1,100,000
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	1,200,000
US Dollar Strengthening [Member]
Summary of Significant Accounting Policies [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	2,000,000
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	4,500,000
Cash, FDIC Insured Amount	250,000
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	$ 32,000,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Quantitative Information One [Member] - $ / shares	1 Months Ended	12 Months Ended
	Aug. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price		$ 0.60	$ 3.49
Contractual term (years)		4 years 8 months 12 days	3 years 1 month 6 days
Volatility (annual)		98.00%	87.00%
Risk-free rate		2.00%	1.00%
Dividend yield (per share)		0.00%	0.00%
Derivative Warrants [Member] | Public and Private Offering [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price		$ 0.36
Contractual term (years)		5 years
Volatility (annual)		99.00%
Risk-free rate		2.00%
Dividend yield (per share)		0.00%
Derivative Warrants [Member] | Debt Conversion [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price		$ 0.48
Contractual term (years)		5 years 6 months
Volatility (annual)		137.00%
Risk-free rate		1.00%
Dividend yield (per share)		0.00%
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price		$ 0.35
Contractual term (years)		2 years 2 months 12 days
Volatility (annual)		84.00%
Risk-free rate		1.00%
Dividend yield (per share)		0.00%
Cognate Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 0.35
Contractual term (years)	2 years 9 months 18 days
Volatility (annual)	81.00%
Risk-free rate	1.00%
Dividend yield (per share)	0.00%

Fair Value Measurements (Deta36

Fair Value Measurements (Details 1) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 4,862	$ 27,982
Share-settled debt (in default)	5,200
Total fair value	10,062
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Total fair value	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Total fair value	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	4,862	$ 27,982
Share-settled debt (in default)	5,200
Total fair value	$ 10,062

Fair Value Measurements (Deta37

Fair Value Measurements (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 27,982	$ 44,742
Extinguishment of derivative liabilities related to Cognate	(10,131)
Extinguishment of warrant liabilities related to warrants exercised for cash	(415)
Warrants granted	5,317
Share-settled debt assumed from Cognate	5,680
Conversion of share-settled debt	(480)
Change in fair value	(17,891)	(15,676)
Cashless warrants exercise		(521)
Warrants exercised for cash		(264)
Redeemable security settlement		(299)
Balance	10,062	27,982
Long-term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	0	0
Share-settled debt assumed from Cognate	5,680
Conversion of share-settled debt	(480)
Change in fair value	0	0
Cashless warrants exercise		0
Warrants exercised for cash		0
Redeemable security settlement		0
Balance	5,200	0
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	27,982	44,742
Extinguishment of derivative liabilities related to Cognate	(10,131)
Extinguishment of warrant liabilities related to warrants exercised for cash	(415)
Warrants granted	5,317
Share-settled debt assumed from Cognate	0
Conversion of share-settled debt	0
Change in fair value	(17,891)	(15,676)
Cashless warrants exercise		(521)
Warrants exercised for cash		(264)
Redeemable security settlement		(299)
Balance	$ 4,862	$ 27,982

Fair Value Measurements (Deta38

Fair Value Measurements (Details Textual) - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	Sep. 16, 2016	Aug. 30, 2016	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2016	Dec. 22, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrants Or Rights, Warrants Issued		6,880,574
Class Of Warrants Or Rights, Warrants Exercised For Cash					2,555,000
Class Of Warrants Or Rights, Replacement Warrants Issued		4,305,772
Class of Warrant or Right, Warrant Issue During Period	1,111,111
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.45	$ 4
Debt Conversion, Converted Instrument, Shares Issued			701,033	322,502
Debt Conversion, Converted Instrument, Amount			$ 4,500,000	$ 200,000	$ 2,500,000
Class Of Warrants Or Rights, Number Of Replacement Warrants Outstanding		4,300,000
Fair Value Of Replacement Warrants		$ 403,000
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.27
Jerry Jasinowski [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Warrant Issue During Period					643,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.35	$ 0.35
Jerry Jasinowski [Member] | Investor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Warrant Issue During Period					15,819,000
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability		$ 10,100,000
Debt Conversion, Converted Instrument, Shares Issued					2,517,000
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					6,034,000

Share-based Compensation (Detai

Share-based Compensation (Details Textual) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 19, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued as compensation				$ 127,000	$ 3,389,000
Stock Issued During Period, Shares, Other			80,068
Cognate Bioservices [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 38,800,000			86,000	2,700,000
Common stock issued as compensation				$ 13,600,000	$ 40,800,000
Shares payment due to Cognate BioServices (in Shares)		8,100,000		175,000	318,116
Others [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued as compensation				$ 41,000	$ 700,000
Stock Issued During Period, Shares, Other				75,000	85,228

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands		Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Gross		$ 720	$ 692
Less: accumulated depreciation		(405)	(216)
Property, Plant and Equipment, Net		315	476
Property, Plant and Equipment Net, Including Construction In Progress		44,874	46,157
Leasehold improvements [Member]
Property, Plant and Equipment, Gross		69	69
Office furniture and equipment [Member]
Property, Plant and Equipment, Gross		25	25
Computer equipment and software [Member]
Property, Plant and Equipment, Gross		626	598
Construction in progress (property in the United Kingdom) [Member]
Property, Plant and Equipment, Net	[1]	$ 44,559	$ 45,681
[1]	Construction in progress includes both the land acquisition costs and the building costs.

Property and Equipment (Detai41

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation	$ 189,000	$ 56,000

Notes Payable (Details)

Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015
Face Value		$ 32,561		$ 23,731
Remaining Debt Discount		(310)
Remaining Deferred Financing Cost		(540)		(925)
Carrying Value		$ 31,711		$ 22,806
Mortgage loan [Member]
Maturity Date		11/16/2017 & 8/16/2017	[1]	11/16/2017 & 8/16/2017
Stated Interest Rate		12.00%	[1]	12.00%
Conversion Price				$ 0
Face Value		$ 10,156	[1]	$ 11,612
Remaining Debt Discount	[1]	0
Remaining Deferred Financing Cost		(365)	[1]	(468)
Carrying Value		$ 9,791	[1]	$ 11,144
2014 Senior convertible notes [Member]
Maturity Date		Aug. 15, 2017		Aug. 15, 2017
Stated Interest Rate		5.00%		5.00%
Conversion Price		$ 6.60		$ 6.60
Face Value		$ 11,000		$ 11,000
Remaining Debt Discount		0
Remaining Deferred Financing Cost		(175)		(457)
Carrying Value		$ 10,825		$ 10,543
Ten Percent Unsecured Debt, Related Party [Member]
Maturity Date		On Demand		On Demand
Stated Interest Rate		10.00%		10.00%
Face Value		$ 50		$ 50
Remaining Debt Discount		0
Remaining Deferred Financing Cost		0		0
Carrying Value		$ 50		$ 50
Twelve Percent Unsecured Debt ,Related Party [Member]
Maturity Date	[2]	On Demand
Stated Interest Rate	[2]	12.00%
Face Value	[2]	$ 260
Remaining Debt Discount	[2]	0
Remaining Deferred Financing Cost	[2]	0
Carrying Value	[2]	$ 260
Ten Percent Unsecured Debt Two [Member]
Maturity Date	[3]	Nov. 4, 2017
Stated Interest Rate	[3]	10.00%
Face Value	[3]	$ 2,450
Remaining Debt Discount	[3]	0
Remaining Deferred Financing Cost	[3]	0
Carrying Value	[3]	$ 2,450
Share Settled Debt [Member]
Maturity Date	[4]	In Default
Stated Interest Rate	[4]	18.00%
Conversion Price	[4]	$ 0.35
Face Value	[4]	$ 5,200
Remaining Debt Discount	[4]	0
Remaining Deferred Financing Cost	[4]	0
Carrying Value	[4]	$ 5,200
Fifteen Percent Unsecured Debt [Member]
Maturity Date				Jul. 31, 2011
Stated Interest Rate				15.00%
Face Value				$ 934
Remaining Deferred Financing Cost				0
Carrying Value				$ 934
Six Percentage Unsecured Debt [Member]
Maturity Date		3/25/2011 & 9/19/2011	[5]	3/25/2011 & 9/19/2011
Stated Interest Rate		6.00%	[5]	6.00%
Conversion Price		$ 3.09	[5]	$ 3.09
Face Value		$ 135	[5]	$ 135
Remaining Debt Discount	[5]	0
Remaining Deferred Financing Cost		0	[5]	0
Carrying Value		$ 135	[5]	$ 135
Eight Percentage Unsecured Debt [Member]
Maturity Date	[6]	Jun. 30, 2018
Stated Interest Rate	[6]	8.00%
Face Value	[6]	$ 3,310
Remaining Debt Discount	[6]	(310)
Remaining Deferred Financing Cost	[6]	0
Carrying Value	[6]	$ 3,000
[1]	On August 17, 2016 and November 17, 2016, the Mortgage loan lender issued two automatic one-year extensions of mortgage loan maturity date to August 16, 2017 and November 16, 2017, with a renewal fees of approximately $0.2 million and $0.3 million, respectively, which are not due until the end of the extension period and were recorded as deferred financing cost. The Company recorded the renewal fees as deferred financing cost on the balance sheet and amortized the renewal fess through the remaining life of the mortgage using a straight-line method.
[2]	On November 28, 2016, Leslie J. Goldman loaned the Company $260,000 pursuant to a Demand Promissory Note (the “Goldman Note”). The Goldman Note bore interest at 12% per annum, and is payable upon demand, with 5 days’ prior written notice by Mr. Goldman to the Company.
[3]	On November 4, 2016, the Company entered into three promissory notes agreement (“the Notes”) with an individual investor for an aggregate amount of $2.45 million. The Notes bore interest at the rate of 10% with 1 year term.
[4]	On October 13, 2016, the Company entered an Assignment and Assumption Agreement (the “Agreement”) with Cognate to assume certain Collateralized Full Recourse Redeemable Notes (the “Notes”) owed by Cognate for total $5.7 million. The Notes were originally due in January 2016 and are currently in default and bore a default interest rate of 18% per annual. During 2016, the Company issued 1,000,000 shares of common stock to convert $480,000 of the Notes. The Company had a $5.2 million principal balance and a $0.2 million accrued interest balance as of December 31, 2016. These Notes settle by providing the debt holder with a variable number of the Company’s shares with an aggregate fair value determined by reference to the debt principal outstanding. Because the value that the holder receives at settlement does not vary with the value of the Company’s equity shares, the settlement provision is not considered a conversion option for financial accounting purposes. Rather, these Notes are recognized as share-settled debt at fair value. The share-settled debt is currently in default.
[5]	This $135,000 note as of December 31, 2016 consists of two separate 6% notes in the amounts of $110,000 and $25,000. In regard to the $110,000 note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $25,000 note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
[6]	On December 30, 2016, the Company entered into a note purchase agreement (the “Note”) with an individual investor for an aggregate principal amount of $3,310,000. The Note bore interest at 8% per annum with 18 months term. The Note carries an original issue discount of $300,000 and $10,000 legal cost that was reimbursable to the investor.

Notes Payable (Details 1)

Notes Payable (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Other interest expenses	$ 6	$ 9
Interest Expense, Debt	3,818	4,153
Amortization of debt discount	0	57
Secured Debt [Member]
Contractual interest	1,259	1,349
Amortization of debt issuance costs	568	582
Interest Expense, Debt	1,827	1,931
Notes Payable, Other Payables [Member]
Interest Expense, Debt	1,152	145
Amortization of debt discount	0	57
15% Unsecured Debt [Member] | Notes Payable, Other Payables [Member]
Interest Expense, Debt	860	140
6% Unsecured Debt [Member] | Notes Payable, Other Payables [Member]
Interest Expense, Debt	7	(70)
Senior Convertiable Note [Member]
Contractual interest	551	640
Accelerated amortization of debt issuance cost due to the conversion of convertible senior notes into common stock	0	302
Amortization of debt issuance costs	282	363
Interest and Debt Expense	833	2,068
Interest Expense, Debt	0	763
Twelve Percent Unsecured Debt ,Related Party [Member] | Notes Payable, Other Payables [Member]
Interest Expense, Debt	3	0
Ten Percent Unsecured Debt Two [Member] | Notes Payable, Other Payables [Member]
Interest Expense, Debt	57	0
Ten Percent Unsecured Debt, Related Party [Member] | Notes Payable, Other Payables [Member]
Interest Expense, Debt	25	18
Share Settled Debt [Member]
Interest Expense, Debt	$ 200	$ 0

Notes Payable (Details Textual)

Notes Payable (Details Textual) - USD ($)	Nov. 11, 2016	Nov. 04, 2016	Oct. 13, 2016	Dec. 30, 2016	Nov. 28, 2016	Aug. 17, 2016	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Oct. 08, 2015
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount							$ 4,500,000	$ 200,000	$ 2,500,000
Debt Instrument, Face Amount									32,561,000	$ 23,731,000
Notes Payable									135,000
Legal Fees									8,941,000	$ 6,577,000
Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Face Amount		$ 2,450,000
Debt Instrument, Term		1 year
Second Mortgage [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	Nov. 16, 2017
Deferred Finance Costs, Current, Net	$ 300,000
Cognate Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount			$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage			18.00%
Long-term Debt, Gross									5,200,000
Debt Instrument, Face Amount			$ 5,700,000
Debt Conversion, Original Debt, Amount			$ 480,000
Interest Payable									200,000
Goldman Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					12.00%						8.00%
Debt Instrument, Face Amount					$ 260,000						$ 400,000
Debt Instrument, Term					5 days
Second Mortgage Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date						Aug. 16, 2017
Deferred Finance Costs, Current, Net						$ 200,000
Six Percentage Note Payable One [Member]
Debt Instrument [Line Items]
Notes Payable									110,000
Six Percentage Note Payable Two [Member]
Debt Instrument [Line Items]
Notes Payable									$ 25,000
Investor [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Instrument, Face Amount				$ 3,310,000
Debt Instrument, Term				18 months
Debt Related Commitment Fees and Debt Issuance Costs				$ 300,000
Legal Fees				$ 10,000

Net Loss per Share Applicable45

Net Loss per Share Applicable to Common Stockholders (Details 1) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	77,024	30,581
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,551	1,551
Common stock warrants equity treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	38,241	14,834
Common stock warrants liability treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	20,037	12,433
Convertible notes and accrued interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,766	1,763
Share Settled Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	15,429	0

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Cognate research and development cost - services	$ 60,081	$ 103,120
Cognate Bioservices [Member]
Related Party Transaction [Line Items]
Cognate research and development cost - services	34,665	37,703
Stock issued to and returned by Cognate	13,654	40,765
Total	$ 48,319	$ 78,468

Related Party Transactions (D47

Related Party Transactions (Details Textual) - USD ($)

Oct. 13, 2016

Sep. 07, 2016

Dec. 22, 2016

Sep. 30, 2016

Sep. 16, 2016

Aug. 30, 2016

Nov. 20, 2015

Oct. 22, 2015

Oct. 19, 2015

Oct. 08, 2015

Jun. 30, 2015

Dec. 31, 2016

Dec. 31, 2015

Nov. 28, 2016

Apr. 26, 2016

Oct. 31, 2015

Apr. 02, 2015

Jan. 17, 2014

Related Party Transaction [Line Items]

Shares Issued, Price Per Share

$ 7.40

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.45

$ 4

Cognate research and development cost - services

$ 60,081,000

$ 103,120,000

Debt Instrument, Face Amount

32,561,000

23,731,000

Shares payment due to Cognate BioServices

3,389,000

Warrant Issuable

3,812,555

Share-Based Compensation

$ 127,000

$ 3,389,000

Stock Outstanding ,Percentage Limit

20.00%

Class of Warrant or Right, Warrant Term

5 years

Common Stock, Shares, Outstanding

157,028,270

95,858,087

Adjustments to Additional Paid in Capital, Other

$ 22,500,000

Due to Related Parties, Current

$ 310,000

$ 50,000

Assignment Agreement [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, New Issues

1,000,000

Shares Issued, Price Per Share

$ 0.48

Related Party Transactions, Initial Obligations

$ 480,000

Due to Related Parties, Current

$ 5,000,000

Goldman Note [Member]

Related Party Transaction [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4.98

Debt Instrument, Face Amount

$ 400,000

$ 260,000

Debt Instrument Repayment, Percentage of Warrants

35.00%

Debt Instrument, Interest Rate, Stated Percentage

8.00%

12.00%

Debt Instrument, Periodic Payment, Total

$ 403,858

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

28,384

Warrant Issued Term

5 years

Condition Two [Member]

Related Party Transaction [Line Items]

Contingent Liability Dcvax Direct Agreement Amount

$ 3,000,000

Condition Three [Member]

Related Party Transaction [Line Items]

Contingent Liability Dcvax Direct Agreement Amount

1,500,000

Condition Four [Member]

Related Party Transaction [Line Items]

Contingent Liability Dcvax Direct Agreement Amount

2,000,000

Condition Five [Member]

Related Party Transaction [Line Items]

Contingent Liability Dcvax Direct Agreement Amount

3,000,000

Condition Six [Member]

Related Party Transaction [Line Items]

Contingent Liability Dcvax Direct Agreement Amount

5,000,000

Cognate Bioservices [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, New Issues

8,052,092

Cognate research and development cost - services

34,665,000

37,703,000

Accounts Payable, Related Parties

$ 221,000

$ 23,400,000

$ 5,500,000

Shares payment due to Cognate BioServices (in Shares)

8,100,000

175,000

318,116

Share-Based Compensation

$ 13,600,000

$ 40,800,000

Stock Repurchased During Period, Shares

731,980

Common Stock, Shares, Outstanding

731,980

Allocated Share-based Compensation Expense

$ 38,800,000

86,000

$ 2,700,000

Due to Related Parties, Current

$ 30,000,000

Accounts Receivable, Net

$ 3,750,000

Cognate Bioservices [Member] | Condition One [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures

8,052,092

8,052,092

Cognate Bioservices [Member] | Condition Two [Member]

Related Party Transaction [Line Items]

Contingent Liability DCVax-L Manufacturing Services Agreement Amount

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4.27

Stock Repurchased During Period, Shares

6,880,574

Class of Warrant or Right, Warrants Issued

4,305,772

Class of Warrant or Right, Warrant Term

5 years

Cognate Bioservices [Member] | Condition Three [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures

5,101,330

Stock Repurchased During Period, Shares

731,980

731,980

Contingent Liability Dcvax Direct Agreement Amount

$ 5,000,000

Cognate [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, New Issues

8,052,092

Lock Up Period Of Conversion Feature

3 years

Shares payment due to Cognate BioServices

$ 3,800,000

Shares payment due to Cognate BioServices (in Shares)

681,884

Allocated Share-based Compensation Expense

$ 38,800,000

Jerry Jasinowski [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, New Issues

1,285,714

Shares Issued, Price Per Share

$ 0.35

Proceeds from Issuance or Sale of Equity

$ 450,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.35

$ 0.35

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

642,857

Class of Warrant or Right, Warrant Term

5 years

Stockholders' Equity (Deficit48

Stockholders' Equity (Deficit) (Details) - $ / shares		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015
Shareholders Deficit [Line Items]
Number of Warrants, Outstanding as of December 31, 2015		27,267	[1]	29,385
Number of Warrants, Warrants granted in a registered direct offering		14,485
Number of Warrants, Warrants granted to Cognate	[2]	35,504
Number of Warrants, Warrants canceled by Cognate		(37,147)
Number of Warrants, Warrants exercised for cash		(15,357)		(1,678)
Number of Warrants, warrants granted		35,287	[3]	1,953
Number of Warrants, Warrants exercised on a cashless basis	[2]			(304)
Number of Warrants, Warrants expired and cancellation		(1,761)		(2,431)
Number of Warrants, Adjustment related to prior issued warrants				280
Number of Warrants, Warrant adjustment due to Cognate price reset				62
Number of Warrants, Outstanding	[1]	58,278		27,267
Weighted Average Exercise Price - Outstanding		$ 4.40	[1]	$ 4.72
Weighted Average Exercise Price - Warrants granted in a registered direct offering		2.70
Weighted Average Exercise Price - Warrants granted to Cognate	[2]	0.69
Weighted Average Exercise Price - Warrants canceled by Cognate		0.35
Weighted Average Exercise Price - Warrants exercised for cash		0.53		4.25
Weighted Average Exercise Price - Warrants granted		0.43	[3]	4.51
Weighted average exercise Price - Warrants exercised on a cashless basis				3.96
Weighted Average Exercise Price - Warrant adjustment due to Cognate price reset				3.35
Weighted Average Exercise Price - Adjustment related to prior issued warrants				4.41
Weighted Average Exercise Price - Warrants expired and cancelled		9.36		4.82
Weighted Average Exercise Price - Outstanding	[1]	$ 1.78		$ 4.40
[1]	Approximately 49,827,000 warrants issued to Cognate and 37,147,000 warrants canceled by Cognate, during the 8-year period from 2008 through 2016, with a weighted average exercise price and remaining contractual term of $4.19 and 2.43 years, respectively. The weighted average exercise price gives effect to adjustments related to the most favored nation clause in these warrants.
[2]	The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period.
[3]	According to the sequencing policy (FN3), the Company classifies these derivative warrant liabilities on the consolidated balance sheet as a current liability.

Stockholders' Equity (Deficit49

Stockholders' Equity (Deficit) (Details Textual) - USD ($)	Oct. 13, 2016	May 15, 2016	May 01, 2015	Apr. 02, 2015	Dec. 22, 2016	Sep. 16, 2016	Feb. 29, 2016	Dec. 24, 2015	Dec. 22, 2015	Oct. 31, 2015	Oct. 19, 2015	Jun. 30, 2015	Apr. 08, 2015	Nov. 30, 2016	Dec. 31, 2016	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Aug. 30, 2016	Jun. 30, 2016
Shareholders Deficit [Line Items]
Stock Issued During Period Shares Exercise of Warrant																		116,675
Shares payment due to Cognate BioServices																					$ 3,389,000
Shares Issued, Price Per Share				$ 7.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																			888,187
Proceeds from Warrant Exercises												$ 3,100,000						$ 800,000	$ 3,700,000	$ 8,066,000	7,430,000
Debt Conversion, Converted Instrument, Amount												$ 4,500,000						$ 200,000		2,500,000
Common stock issued as compensation																				$ 127,000
Warrants Issued During Period																				49,827,000
Stock Issued During Period, Value, New Issues																					$ 81,662,000
Stock Issued During Period, Shares, Other																			80,068
Adjustments To Additional Paid In Capital Redeemable Securities Settlement Value																			$ 300,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants																			385,000
Stock Issued During Period, Shares, Acquisitions			3,851,351	5,405,405									1,554,054
Common Stock, Par Or Stated Value Per Share				$ 0.001											$ 0.001					$ 0.001	$ 0.001
Stock Issued During Period, Value, Acquisitions			$ 28,500,000	$ 40,000,000									$ 11,500,000
Sale of Stock, Transaction Date			May 1, 2015										Apr. 8, 2015
Stock Issued During Period, Exercise Of Warrants												723,422
Stock Issued During Period, Shares, Extinguishment of warrant liabilities												9,200						57,500
Stock Issued During Period, Value, Extinguishment of warrant liabilities												$ 60,000
Debt Conversion, Converted Instrument, Shares Issued												701,033						322,502
Fair Value Adjustment of Warrants																			$ 500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.45																$ 4
Proceeds From Sale Of Available Securities Gross							$ 10,000,000
Proceeds from Sale of Available-for-sale Securities, Total							$ 9,200,000
Deemed dividend Related To Warrant Modification		$ 2,600,000																		$ 5,647,000	$ 0
Payments of Stock Issuance Costs															$ 321,000					1,077,000	0
Class of Warrant or Right, Warrant Term						5 years
Class Of Warrant Or Right, Increase decrease Warrant Exercise Value																$ 3,000,000
Class of Warrant or Right, Warrant Issue During Period						1,111,111
Warrants Not Settleable in Cash, Fair Value Disclosure															$ 4,200,000					4,200,000
Gain (Loss) on Extinguishment of Debt																				$ (1,152,000)	$ 0
Class Of Warrant Or Right, Non Cognate Warrants Cancelled																				37,147
Accured Interest [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share															$ 0.50					$ 0.50
Debt Conversion, Converted Instrument, Amount						$ 1,000,000
Stock Issued During Period, Value, New Issues															$ 1,500,000
Stock Issued During Period, Shares, New Issues															2,812,174
Debt Conversion, Converted Instrument, Shares Issued						2,222,222
Class of Warrant or Right, Warrant Term															5 years
Class of Warrant or Right, Warrant Issue During Period															1,406,086
Warrants Not Settleable in Cash, Fair Value Disclosure															$ 600,000					$ 600,000
Interest Payable															1,500,000					$ 1,500,000
Gain (Loss) on Extinguishment of Debt															$ 700,000
Placement Agent [Member]
Shareholders Deficit [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value																$ 0.44
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted																263,122
Scientific Board [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share															$ 0.49					$ 0.49
Stock Issued During Period, Shares, New Issues															60,000
Scientific Board [Member] | Research and Development Expense [Member]
Shareholders Deficit [Line Items]
Allocated Share-based Compensation Expense															$ 29,400
Equity Unit Purchase Agreements [Member]
Shareholders Deficit [Line Items]
Proceeds from Warrant Exercises																$ 3,400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																10,945,694
Class of Warrant or Right, Warrant Term																5 years
Payments for Other Fees																$ 454,000
Series A Warrants [Member]
Shareholders Deficit [Line Items]
Sale of Stock, Number of Shares Issued in Transaction							5,882,353
Sale of Stock, Price Per Share							$ 1.70
Warrant Issued to Purchase Common Stock							2,941,177
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.25
Series B Warrants [Member]
Shareholders Deficit [Line Items]
Proceeds from Warrant Exercises		$ 4,235,000
Warrant Issued to Purchase Common Stock		4,411,764					5,882,353
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.96					$ 3
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,411,764
Series C Warrants [Member]
Shareholders Deficit [Line Items]
Warrant Issued to Purchase Common Stock							2,941,177
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,205,882
Class of Warrant or Right, Warrant Term							5 years
Series A and Series C Warrants [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Series D Warrants [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,205,882
New Warrants [Member] | Equity Unit Purchase Agreements [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 0.44
Private Placement [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																	$ 2.125						$ 1.20
Percentage Of Placement Fees On Aggregate Purchase Price Of Common Stock Sold																	7.00%			7.00%
Percentage Of Common Stock Warrants Issuable On Aggregate Number Of Shares Of Common Stock Sold																	5.00%			5.00%
Class Of Warrant Or Right Exercise Price Percentage On Public Offering Price																	125.00%			125.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																	294,118						220,588
Direct Offering [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share															$ 0.35	$ 0.50				$ 0.35
Stock Issued During Period, Shares, New Issues															28,575,000	7,400,000
Proceeds from Issuance of Common Stock																$ 3,400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 0.35	$ 0.60				$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															14,287,500	3,700,000				14,287,500
Payments of Stock Issuance Costs															$ 800,000
Class of Warrant or Right, Warrant Term															5 years	5 years
Proceeds from Issuance or Sale of Equity															$ 9,200,000
Investor [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 0.42
Class of Warrant or Right, Warrant Term																5 years
Class of Warrant or Right, Warrant Issue During Period																1,286,111
Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Shares payment due to Cognate BioServices (in Shares)												8,100,000								175,000	318,116
Debt Conversion, Converted Instrument, Amount															$ 480,000
Stock Issued During Period, Shares, New Issues											8,052,092
Debt Conversion, Converted Instrument, Shares Issued															1,000,000
Allocated Share-based Compensation Expense											$ 38,800,000									$ 86,000	$ 2,700,000
Multiple Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period Shares Issued For Cash 1																		2,566
Stock Issued During Period, Exercise Of Warrants												183,895
individual Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period Shares Exercise of Warrant												85,228
Common stock issued as compensation												$ 700,000
Woodford [Member]
Shareholders Deficit [Line Items]
Shares payment due to Cognate BioServices (in Shares)										681,884
Shares payment due to Cognate BioServices										$ 3,800,000
Sale of Stock, Price Per Share										$ 5.50
Stock Issued During Period, Shares, Acquisitions										5,454,545
Common Stock, Par Or Stated Value Per Share										$ 0.001
Stock Issued During Period, Value, Acquisitions										$ 30,000,000
Healthcare Focused Institutional Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, New Issues								$ 12,600,000
Proceeds from Issuance of Common Stock								$ 11,650,000
Jerry Jasinowski [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share					$ 0.35
Stock Issued During Period, Shares, New Issues					1,285,714
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.35										$ 0.35					$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					642,857
Class of Warrant or Right, Warrant Term					5 years
Class of Warrant or Right, Warrant Issue During Period																				643,000
Proceeds from Issuance or Sale of Equity					$ 450,000
Jerry Jasinowski [Member] | Private Placement [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share					$ 0.35
Stock Issued During Period, Shares, New Issues					1,285,714
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					642,857
Class of Warrant or Right, Warrant Term					5 years
Proceeds from Issuance or Sale of Equity					$ 450,000
Common Stock [Member]
Shareholders Deficit [Line Items]
Shares payment due to Cognate BioServices (in Shares)																					403
Shares payment due to Cognate BioServices																					$ 0
Common stock issued as compensation																				$ 0
Stock Issued During Period, Value, New Issues																					$ 14,000
Stock Issued During Period, Shares, New Issues																					14,360
Stock Issued During Period, Shares, Other																				41,857
Debt Conversion, Converted Instrument, Shares Issued																				6,034,000
Common Stock [Member] | Investor [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share														$ 0.53		$ 0.36
Stock Issued During Period, Shares, New Issues														2,518,687		2,572,216
Proceeds from Issuance of Common Stock																$ 900,000
Proceeds from Issuance or Sale of Equity														$ 1,300,000
Common Stock [Member] | Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Shares payment due to Cognate BioServices (in Shares)												318,116
Common Stock [Member] | Healthcare Focused Institutional Investors [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share									$ 3.60
Stock Issued During Period, Shares, New Issues									3,500,000
Common Stock, Par Or Stated Value Per Share									$ 0.001
Warrant [Member]
Shareholders Deficit [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																				2,517,000
Derivative, Fair Value, Net						$ 400,000										$ 400,000
Warrant [Member] | Investor [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 0.51
Class of Warrant or Right, Warrant Term	5 years													5 years
Class of Warrant or Right, Warrant Issue During Period														1,259,345
Warrant [Member] | Healthcare Focused Institutional Investors [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share									$ 4.50
Stock Issued During Period, Shares, New Issues									1,750,000
Additional Paid-in Capital [Member]
Shareholders Deficit [Line Items]
Shares payment due to Cognate BioServices																					$ 3,389,000
Common stock issued as compensation																				$ 127,000
Stock Issued During Period, Value, New Issues																					$ 81,648,000
Stock Issued During Period, Value, Extinguishment of warrant liabilities																		$ 2,000,000
Maximum [Member]
Shareholders Deficit [Line Items]
Warrants Issued, Weighted Average Remaining Contractual Term																				2 years 5 months 5 days
Class of Warrant or Right, Exercise Price of Warrants or Rights																						$ 4.27
Minimum [Member]
Shareholders Deficit [Line Items]
Warrants Issued, Weighted Average Remaining Contractual Term																				4 years 2 months 8 days

Variable Interest Entities (Det

Variable Interest Entities (Details Textual) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($)	1 Months Ended
	Oct. 31, 2016	Dec. 31, 2016
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Liabilities	$ 5,700,000
Variable Interest Entity, Financial or Other Support, Amount	$ 3.8
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount		$ 4,500,000

Commitments and Contingencies51

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2016USD ($)
Commitments And Contingencies [Line Items]
2,017	$ 557
2,018	120
Total	677
Germany [Member]
Commitments And Contingencies [Line Items]
2,017	64
2,018	0
Total	64
U.S [Member]
Commitments And Contingencies [Line Items]
2,017	318
2,018	81
Total	399
UNITED KINGDOM
Commitments And Contingencies [Line Items]
2,017	175
2,018	39
Total	$ 214

Commitments and Contingencies52

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Mar. 26, 2016	Oct. 28, 2013	Jul. 31, 2012	Dec. 31, 2016	Dec. 31, 2015	Jan. 17, 2014
Commitments And Contingencies [Line Items]
Office Space Taken Under Lease Agreement	505 square feet		7,097 square feet
Operating Leases, Rent Expense				$ 300,000	$ 300,000
UNITED KINGDOM
Commitments And Contingencies [Line Items]
Office Space Taken Under Lease Agreement		4,251 square feet
Operating Leases, Rent Expense				$ 120,000
Condition Two [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						$ 3,000,000
Condition Three [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						1,500,000
Condition Four [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						2,000,000
Condition Five [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						3,000,000
Condition Six [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						5,000,000
DCVax-Direct Agreement [Member] | Condition One [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						3,000,000
DCVax-Direct Agreement [Member] | Condition Two [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						5,000,000
DCVax-Direct Agreement [Member] | Condition Three [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						1,500,000
DCVax-Direct Agreement [Member] | Condition Four [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						2,000,000
DCVax-Direct Agreement [Member] | Condition Five [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						3,000,000
DCVax-Direct Agreement [Member] | Condition Six [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount						$ 5,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax asset
Net operating loss carryforward	$ 204,106	$ 180,927
Research and development credit carry forwards	14,911	12,661
Stock based compensation and other	17,106	24,759
Total deferred tax assets	236,123	218,347
Valuation Allowance	(236,123)	(218,347)
Deferred tax asset, net of allowance	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statutory federal income tax rate	34.00%	34.00%
State taxes, net of federal tax benefit	1.80%	5.40%
Tax rate differential on foreign income	(2.30%)	0.00%
Derivative gain or loss and other	7.60%	5.80%
Cancellation of shares	(16.60%)	0.00%
Cancellation of warrants	(7.80%)	0.00%
R&D Credit	2.80%	2.60%
Other permanent items and true ups	2.70%	0.00%
Change in valuation allowance	(22.20%)	(47.80%)
Income tax provision (benefit)	0.00%	0.00%

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Federal
Current	$ 0	$ 0
Deferred	(11,160)	(41,583)
State
Current	0	0
Deferred	(1,427)	(6,659)
Foreign
Current	0	0
Deferred	(5,189)	0
Change in valuation allowance	17,776	48,242
Income tax provision (benefit)	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) $ in Millions	Dec. 31, 2016USD ($)
Income Taxes [Line Items]
Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development	$ 14.9
Operating Loss Carryforwards	507.5
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 17.7

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)

Mar. 09, 2017

Mar. 03, 2017

Mar. 01, 2017

Jun. 20, 2017

May 20, 2017

Apr. 19, 2017

Mar. 30, 2017

Mar. 17, 2017

Jun. 30, 2015

Sep. 30, 2015

Dec. 31, 2016

Mar. 31, 2017

Sep. 16, 2016

Aug. 30, 2016

Dec. 31, 2015

Apr. 02, 2015

Subsequent Event [Line Items]

Shares Issued, Price Per Share

$ 7.40

Common Stock, Par Or Stated Value Per Share

$ 0.001

$ 0.001

$ 0.001

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.45

$ 4

Debt Conversion, Converted Instrument, Amount

$ 4,500,000

$ 200,000

$ 2,500,000

Debt Instrument, Face Amount

$ 32,561,000

$ 23,731,000

Convertible Senior Notes [Member] | Scenario, Forecast [Member]

Subsequent Event [Line Items]

Debt Instrument, Repurchase Amount

$ 5,500,000

$ 2,500,000

$ 2,000,000

Repayments of Debt

$ 5,500,000

$ 2,500,000

$ 2,000,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Shares Issued, Price Per Share

$ 0.26

Stock Issued During Period, Shares, New Issues

2,500,000

18,800,000

Common Stock, Par Or Stated Value Per Share

$ 0.001

Proceeds from Issuance or Sale of Equity

$ 7,500,000

Minimum Beneficial Ownership Percentage

4.99%

Subsequent Event [Member] | NonConvertible Promissory Notes [Member]

Subsequent Event [Line Items]

Debt Instrument, Term

6 months

6 months

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

$ 1,155,000

$ 2,020,000

Debt Instrument Discount Percentage

10.00%

3.00%

Proceeds from Issuance of Debt

$ 1,000,000

$ 1,959,400

Debt Repayments With out Penalty, Expected Minimum Capital Rise

$ 5,000,000

$ 15,000,000

Subsequent Event [Member] | Class A Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.26

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

21,600,000

Class of Warrants, Expiration Term

5 years

Subsequent Event [Member] | Class B Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 1

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

21,600,000

Subsequent Event [Member] | Class C Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.26

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

10,000,000

Class Of Warrant Or Right Prefunded Exercise Price

$ 0.25

Class Of Warrant Or Right Exercise Price, Payable On exercise Of Warrant

$ 0.01

Subsequent Event [Member] | Convertible Senior Notes [Member]

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

7.00%

Debt Conversion, Converted Instrument, Amount

$ 1,500,000

Debt Instrument, Repurchase Amount

$ 500,000

$ 500,000

Debt Instrument, Convertible, Conversion Price

$ 0.3713

Debt Instrument Repayments Description

payment, when any cumulative financing of new cash during the period of the Note Repurchase Agreement exceeds $15 million, of 30% of such excess amount to repurchase Notes from the Holders within three business days of the closing of any such raise.